

# Table of Contents

## **PART I. BACKGROUND AND GENERAL ANTITRUST PRINCIPLES**

### **CHAPTER 1. GENERAL BACKGROUND**

- § 1:1 Synopsis and introduction
- § 1:2 Purpose and definition of the antitrust laws
- § 1:3 Overview and history of the antitrust laws
- § 1:4 The goals of antitrust
- § 1:5 Is health care different?
- § 1:6 History of antitrust enforcement in the health-care sector
- § 1:7 Current health-care antitrust enforcement initiatives
- § 1:8 Federal government antitrust guidelines
- § 1:9 Conclusion
- § 1:10 Antitrust resources

### **CHAPTER 2. INTERSTATE COMMERCE AND RELEVANT ANTITRUST MARKETS**

- § 2:1 Synopsis and introduction
- § 2:2 The interstate commerce requirement
- § 2:3 Relevant antitrust markets
- § 2:4 —Relevant product market
- § 2:5 —Relevant geographic market
- § 2:6 Conclusion

### **CHAPTER 3. SECTION 1 OF THE SHERMAN ANTITRUST ACT: FUNDAMENTAL CONCEPTS**

- § 3:1 Synopsis and introduction
- § 3:2 Elements of a section 1 violation
- § 3:3 —Agreement
- § 3:4 — —Nature of the agreement

- § 3:5 — —Capacity to conspire
- § 3:6 — —Conspiracy in fact
- § 3:7 — —Anticompetitive purpose or intent
- § 3:8 — —Purpose and intent in civil antitrust cases
- § 3:9 — —Intent in criminal antitrust cases
- § 3:10 — —Unreasonably anticompetitive effect
- § 3:11 — —The rule of reason
- § 3:12 — —The per se rule
- § 3:13 — —Hybrid analyses—The “quick look” rule
- § 3:14 The antitrust guidelines for collaborations among competitors

#### **CHAPTER 4. SECTION 1 OF THE SHERMAN ANTITRUST ACT: HORIZONTAL AGREEMENTS**

- § 4:1 Synopsis and introduction
- § 4:2 Horizontal price-fixing agreements
- § 4:3 Agreements to exchange or disseminate information
- § 4:4 Horizontal market-allocation agreements
- § 4:5 Bid-rigging agreements
- § 4:6 Covenants not to compete
- § 4:7 Concerted refusals to deal
- § 4:8 Mergers and joint ventures
- § 4:9 Unfair competition and “dirty tricks”
- § 4:10 Standard-setting programs

#### **CHAPTER 5. SECTION 1 OF THE SHERMAN ANTITRUST ACT: VERTICAL AGREEMENTS**

- § 5:1 Synopsis and introduction
- § 5:2 Vertical price-fixing agreements
- § 5:3 Vertical market-allocation agreements
- § 5:4 Distributorship terminations
- § 5:5 Dual distribution
- § 5:6 Tying agreements
- § 5:7 Exclusive dealing agreements
- § 5:8 Reciprocal dealing agreements
- § 5:9 Price discrimination and commercial bribery

TABLE OF CONTENTS

**CHAPTER 6. SECTION 2 OF THE  
SHERMAN ACT**

- § 6:1 Synopsis and introduction
- § 6:2 Monopolization
- § 6:3 —Monopoly power
- § 6:4 —Anticompetitive conduct
- § 6:5 — —Monopoly pricing
- § 6:6 — —Predatory pricing
- § 6:7 — —Refusals to deal
- § 6:8 — —Denial of access to an essential facility
- § 6:9 — —Leveraging
- § 6:10 — —Vertical integration
- § 6:11 — —Mergers
- § 6:12 — —Other predatory or unreasonably  
exclusionary conduct
- § 6:13 Attempted monopolization
- § 6:14 —Specific intent and predatory conduct
- § 6:15 —Dangerous probability of success
- § 6:16 Conspiracy to monopolize
- § 6:17 “Shared monopoly”

**CHAPTER 7. PRICE DISCRIMINATION,  
INTERLOCKING DIRECTORATES, AND  
UNFAIR METHODS OF COMPETITION**

- § 7:1 Synopsis and introduction
- § 7:2 The Robinson-Patman Act—Overview
- § 7:3 —Section 2(a)—Essential elements
- § 7:4 — —Jurisdictional requirements
- § 7:5 — —Competitive effects
- § 7:6 — —Defenses
- § 7:7 —Section 2(c)
- § 7:8 —Sections 2(d) and 2(e)
- § 7:9 —Section 2(f)
- § 7:10 —Exemptions and applicability
- § 7:11 —Injury in private treble-damage litigation
- § 7:12 Section 8 of the Clayton Act
- § 7:13 The Federal Trade Commission Act

**CHAPTER 8. SECTION 7 OF THE  
CLAYTON ACT: MERGERS AND  
ACQUISITIONS**

- § 8:1 Synopsis and introduction

- § 8:2 Preliminary issues
- § 8:3 An overview of merger analysis and the effect of  
the 2010 *Merger Guidelines*
- § 8:4 Relevant markets
- § 8:5 Horizontal mergers
- § 8:6 —Concentration
- § 8:7 —Other factors
- § 8:8 — —Rebuttal evidence
- § 8:9 — — —Entry
- § 8:10 — — —Market characteristics and ease of  
collusion
- § 8:11 — — —Financial viability
- § 8:12 — — —Efficiencies from the merger
- § 8:13 —Defenses
- § 8:14 Vertical mergers
- § 8:15 Conglomerate mergers
- § 8:16 Joint ventures
- § 8:17 Premerger notification requirements
- § 8:18 Relief—Antitrust Division and Federal Trade  
Commission
- § 8:19 —Private parties
- § 8:20 Conclusion

## **CHAPTER 9. ANTITRUST EXEMPTIONS AND IMMUNITIES**

- § 9:1 Synopsis and introduction
- § 9:2 Nonprofit entities and noncommercial conduct
- § 9:3 Federal governmental immunity
- § 9:4 Express immunity
- § 9:5 Implied repeal
- § 9:6 Primary and exclusive jurisdiction
- § 9:7 State-action exemption
- § 9:8 Solicitation of government action
- § 9:9 Local Government Antitrust Act
- § 9:10 Business of insurance
- § 9:11 Labor
- § 9:12 Health Care Quality Improvement Act

## **CHAPTER 10. ENFORCEMENT BY THE ANTITRUST DIVISION AND FEDERAL TRADE COMMISSION**

- § 10:1 Introduction

## TABLE OF CONTENTS

- § 10:2 The Antitrust Division—Organization
- § 10:3 —Criminal enforcement
- § 10:4 —Civil enforcement
- § 10:5 —Relief in civil cases
- § 10:6 —Business review procedure
- § 10:7 The Federal Trade Commission—Organization  
and authority
- § 10:8 —Investigations and litigation
- § 10:9 —Advisory opinions

## **CHAPTER 11. PRIVATE ACTIONS UNDER THE ANTITRUST LAWS**

- § 11:1 Synopsis and introduction
- § 11:2 Elements of a damage action
- § 11:3 —Injury
- § 11:4 —Business or property
- § 11:5 —Causation
- § 11:6 —Antitrust injury
- § 11:7 —Antitrust standing
- § 11:8 —Damages
- § 11:9 Affirmative defenses
- § 11:10 —Statute of limitations
- § 11:11 —In pari delicto and related defenses
- § 11:12 —Antitrust defenses in nonantitrust cases
- § 11:13 Parties liable
- § 11:14 Effect of government judgments and prior  
violations
- § 11:15 Injunctive relief

## **CHAPTER 12. MOTIONS TO DISMISS AND SUMMARY JUDGMENT MOTIONS IN ANTITRUST CASES**

- § 12:1 Synopsis and introduction
- § 12:2 Motions to dismiss for failure to state a claim in  
antitrust cases
- § 12:3 Summary judgment motions in antitrust cases

# Table of Contents

## **PART II. APPLICATION OF ANTITRUST PRINCIPLES TO THE HEALTH CARE SECTOR**

### **CHAPTER 13. PRACTITIONER CREDENTIALING BASED ON PEER REVIEW**

- § 13:1 Synopsis and introduction
- § 13:2 Hospital organization and the credentialing process
- § 13:3 Legal theories and parties
- § 13:4 Preliminary issues
- § 13:5 —Interstate commerce
- § 13:6 —State-action exemption
- § 13:7 —Local Government Antitrust Act
- § 13:8 —Health Care Quality Improvement Act
- § 13:9 Antitrust standing
- § 13:10 Analysis under Section 1 of the Sherman Act
- § 13:11 —Capacity to conspire
- § 13:12 —Conspiracy in fact
- § 13:13 —Standard of analysis
- § 13:14 —Analysis under the rule of reason
- § 13:15 — —Relevant market
- § 13:16 — —Effect on competition
- § 13:17 — —Intent and purpose
- § 13:18 Analysis under Section 2 of the Sherman Act
- § 13:19 Allied-Health practitioners
- § 13:20 Discovery in staff-privilege antitrust litigation
- § 13:21 Minimizing antitrust risks

### **CHAPTER 14. EXCLUSIVE CONTRACTS BETWEEN HOSPITALS AND PHYSICIANS**

- § 14:1 Synopsis and introduction

- § 14:2 Antitrust theories
- § 14:3 Hospital-physician exclusive contracts as tying arrangements
- § 14:4 —Separate and distinct products
- § 14:5 —Sale of one service conditioned on purchase of another
- § 14:6 —Market power in the market for the tying product
- § 14:7 —Effect on substantial amount of interstate commerce
- § 14:8 —Economic interest in sale of tied product
- § 14:9 —Legitimate business justification
- § 14:10 Exclusive-dealing agreements
- § 14:11 —Relevant market
- § 14:12 —Effect on competition
- § 14:13 Exclusive contracts as violations of Section 2 of the Sherman Act
- § 14:14 Departmental closings
- § 14:15 Exclusive contracts and vertical price-fixing agreements
- § 14:16 Minimizing antitrust risk

## **CHAPTER 15. MERGERS IN THE HEALTH CARE SECTOR**

- § 15:1 Synopsis and introduction
- § 15:2 Preliminary issues—The economic effects of mergers
- § 15:3 —The relevant federal antitrust statutes
- § 15:4 —Virtual mergers and single-entity status
- § 15:5 —Section 7 and acquisitions by nonprofit entities
- § 15:6 —State-action exemption
- § 15:7 —Interstate commerce
- § 15:8 —Premerger notification, investigation, and preliminary relief
- § 15:9 Analyzing hospital mergers
- § 15:10 —Relevant product market
- § 15:11 —Relevant geographic market
- § 15:12 —Competitor identification and market share calculation
- § 15:13 —Potential harms—Unilateral effects and coordinated effects
- § 15:14 —Unilateral effects

## TABLE OF CONTENTS

- § 15:15 —Coordinated effects
- § 15:16 —Rebutting the prima facie case
- § 15:17 — —Low entry barriers
- § 15:18 — —Efficiencies
- § 15:19 — —Weakened competitor or “flailing firm”
- § 15:20 — —Failing firm defense
- § 15:21 —Other factors
- § 15:22 — —The Affordable Care Act and health-care reform
- § 15:23 — —Size and sophistication of purchasers
- § 15:24 — —Opinions of purchasers and purchaser complaints
- § 15:25 — —Opinions of competitors and competitor complaints
- § 15:26 — —Party and consultant statements and documents about purpose and effect
- § 15:27 — —Public and private commitments restraining exercise market power
- § 15:28 — —Nonprofit status
- § 15:29 Cross-market and vertical mergers
- § 15:30 Planning a hospital merger—Danger signs—  
Early counsel involvement
- § 15:31 Other health-care sector mergers
- § 15:32 —Physician practice mergers—Hospital acquisitions of physician practices
- § 15:33 —Health-plan mergers
- § 15:34 —Other health-care sector industry mergers
- § 15:35 State merger notification laws
- § 15:36 FTC frequently asked questions about merger consent order provisions

## **CHAPTER 16. JOINT VENTURES IN THE HEALTH CARE SECTOR**

- § 16:1 Synopsis and introduction
- § 16:2 Definition of joint venture
- § 16:3 Classifications of joint ventures
- § 16:4 Analyzing the joint venture’s formation
- § 16:5 Analyzing agreements relating to the joint venture’s operation
- § 16:6 Overview of the *Collaboration Guidelines*
- § 16:7 Analyzing particular joint ventures
- § 16:8 —Group purchasing programs

- § 16:9 —Joint ventures among competitors to provide new services, expensive equipment, and specialized services
- § 16:10 —Joint ventures between hospitals and physicians
- § 16:11 Practical factors and danger signals

## **CHAPTER 17. PROVIDER DIVERSIFICATION**

- § 17:1 Synopsis and introduction
- § 17:2 Relevant legal theories
- § 17:3 Diversification and Section 1 of the Sherman Act
- § 17:4 —Diversification resulting from an exclusive dealing agreement
- § 17:5 —Diversification resulting in a tying arrangement
- § 17:6 —Diversification and reciprocal dealing
- § 17:7 Diversification and Section 7 of the Clayton Act
- § 17:8 Diversification and Section 2 of the Sherman Act—Monopolization and attempted monopolization
- § 17:9 —Diversification and predatory refusals to deal
- § 17:10 —Diversification and the essential facilities doctrine
- § 17:11 —Diversification and leveraging
- § 17:12 —Steering as predatory conduct
- § 17:13 Risk minimization in hospital diversification
- § 17:14 Diversification and steering by other providers

## **CHAPTER 18. COMPETITION BETWEEN HOSPITALS AND PHYSICIAN-OWNED FACILITIES**

- § 18:1 Synopsis and introduction
- § 18:2 Issue background
- § 18:3 Actions to combat competition from medical-staff members
- § 18:4 Ethical restraints: Employee non-compete agreements
- § 18:5 Application of antitrust principles

TABLE OF CONTENTS

**CHAPTER 19. PRICE-FIXING AGREEMENTS AND PRICE AND WAGE EXCHANGES AMONG COMPETITORS**

- § 19:1 Synopsis and introduction
- § 19:2 Provider price-fixing agreements, generally
- § 19:3 “Naked” price-fixing agreements
- § 19:4 Forms of provider price-fixing agreements
- § 19:5 Concerted negotiations among providers with payers
- § 19:6 Agreements among competitors to exchange or disseminate pricing information

**CHAPTER 20. PROVIDER-CONTROLLED CONTRACTING NETWORKS**

- § 20:1 Synopsis and introduction
- § 20:2 Provider-controlled contracting networks
- § 20:3 —Price-fixing agreements
- § 20:4 —Statement 8—Physician network joint ventures
- § 20:5 — —Financial risk sharing and the “antitrust safety zones”
- § 20:6 — —Participation percentages, exclusivity, and the safety zones
- § 20:7 — —Outside the safety zones
- § 20:8 — —Outside the safety zones: Ancillary price-fixing agreements and clinical integration
- § 20:9 — —Physician network joint ventures: Market power
- § 20:10 —Statement 9—Multiprovider networks
- § 20:11 — —Price-fixing agreements in multiprovider networks
- § 20:12 — —Market power in multiprovider networks
- § 20:13 — —Vertical agreements in multiprovider networks
- § 20:14 —Messenger arrangements
- § 20:15 —The Federal Trade Commission and Department of Justice Statement of Antitrust Enforcement Policy Regarding Accountable Care Organizations Participating in the Medicare Shared Savings Program

## **CHAPTER 21. HEALTH PLAN MARKET POWER AND PROVIDER EXCLUSIONS FROM NETWORKS**

- § 21:1 Synopsis and introduction
- § 21:2 Effect of the McCarran-Ferguson Act
- § 21:3 Participation agreements between providers and payers
- § 21:4 Payer monopsony power
- § 21:5 —Payer monopsony power and low reimbursement
- § 21:6 —Payer monopsony power and most-favored-nations provisions
- § 21:7 —Payer monopsony power and all-products provisions
- § 21:8 Exclusion of providers from health plans or contracting networks—Generally
- § 21:9 —Selective and exclusive contracting

## **CHAPTER 22. MARKET-ALLOCATION AGREEMENTS, HEALTH PLANNING, AND CERTIFICATES OF NEED**

- § 22:1 Synopsis and introduction
- § 22:2 The Health Planning Act and the antitrust laws
- § 22:3 CON pros and cons—Agency opposition
- § 22:4 Antitrust ramifications of certificate-of-need proceedings
- § 22:5 Health-planning activities and horizontal market-allocation agreements
- § 22:6 Conclusion

## **CHAPTER 23. RESALES OF PREFERENTIALLY PRICED COMMODITIES: THE ROBINSON- PATMAN AND NONPROFIT INSTITUTIONS ACTS**

- § 23:1 Synopsis and introduction
- § 23:2 Overview of Robinson-Patman Act
- § 23:3 The Non-Profit Institutions Act (NPIA)
- § 23:4 NPIA court decisions
- § 23:5 FTC NPIA advisory opinions

TABLE OF CONTENTS

§ 23:6 Practical considerations and principles

**CHAPTER 24. ETHICAL RESTRAINTS**

- § 24:1 Synopsis and introduction
- § 24:2 Generally applicable antitrust principles
- § 24:3 Ethical restraints: Price-fixing agreements
- § 24:4 Ethical restraints: Agreements not to engage in competitive bidding
- § 24:5 Ethical restraints: Limitations on “poaching”
- § 24:6 Ethical restraints: Limitations on advertising
- § 24:7 Ethical restraints: Restraints on practice form
- § 24:8 Ethical restraints: Membership restrictions
- § 24:9 Ethical restraints: Standards of practice relating to quality
- § 24:10 Conclusion

**CHAPTER 25. PAY FOR DELAY AGREEMENTS**

- § 25:1 Overview
- § 25:2 Recent pay for delay cases

**CHAPTER 26. ANTITRUST IMPLICATIONS AND THE “ORANGE BOOK”**

- § 26:1 Antitrust Implications of listing a drug in FDA’s “Orange Book” of approved drugs

**Table of Laws and Rules**

**Table of Cases**

**Index**

## **PART III**

### **APPENDIXES**

- Appendix A. Statutes
- Appendix A1. Excerpts from the Sherman Act (15 U.S.C.A. §§ 1 to 8)
- Appendix A2. Excerpts from the Clayton Act (15 U.S.C.A. §§ 12, 14 to 27; 29 U.S.C.A. § 52 (2000))
- Appendix A3. Excerpts from the Robinson- Patman Act (15 U.S.C.A. §§ 13, 13a, 13b, 21a (2000))
- Appendix A4. The Nonprofit Institutions Act (15 U.S.C.A. § 13c (2000))
- Appendix A5. Excerpts from the Federal Trade Commission Act (15 U.S.C.A. §§ 41 to 58 (2000))
- Appendix A6. The Local Government Antitrust Act (15 U.S.C.A. §§ 34 to 36 (2000))
- Appendix A7. The McCarran-Ferguson Act (15 U.S.C.A. §§ 1011 to 1015 (2000))
- Appendix A8. The Health Care Quality Improvement Act (42 U.S.C.A. §§ 11101 to 11152 (2000))
- Appendix A9. The Antitrust Civil Process Act (15 U.S.C.A. §§ 1311 to 1314 (2000))
- Appendix B. Mergers
- Appendix B1. 2010 U.S. Department of Justice & Federal Trade Commission Horizontal Merger Guidelines (Aug. 19, 2010)
- Appendix B2. Federal Trade Commission Statement Concerning Horizontal Mergers (1982)
- Appendix B3. Premerger Notification Form and Instructions Under Amended Section 7A of the Clayton Act

HEALTH CARE & ANTITRUST LAW

- Appendix B3A. Federal Trade Commission Premerger Notification Office Style Sheet for Hart-Scott-Rodino Filings
- Appendix B3B. Federal Trade Commission Premerger Notification Office Hart-Scott-Rodino Filing Fee Information
- Appendix B3C. U.S. Department of Justice Antitrust Division Merger Review Process Initiative (Oct. 12, 2001)
- Appendix B3D. U.S. Department of Justice Antitrust Division Second Request Internal Appeal Procedure (June 2001)
- Appendix B3E. Federal Trade Commission Memo to Staff Concerning Merger Investigations (May 16, 2000)
- Appendix B3F. Statement of the Federal Trade Commission's Bureau of Competition on Guidelines for Merger Investigations (Dec. 11, 2002)
- Appendix B3G. Protocol for Coordination in Merger Investigations Between the Federal Enforcement Agencies and State Attorneys General
- Appendix B3H. Federal Trade Commission Second-Request Form Letter
- Appendix B4. U.S. Department of Justice Antitrust Division Business Review Procedure
- Appendix B5. Federal Trade Commission Advisory Opinions Procedure
- Appendix B6. 1984 U.S. Department of Justice Merger Guidelines
- Appendix B7. Antitrust Division Policy Guide to Merger Remedies
- Appendix B8. Federal Trade Commission Appeal Procedure for Requests for Additional Information
- Appendix B9. DOJ Model Document—Request for Additional Information and Documentary Material Issued to [Weebyewe Corporation] (February 2021)

- Appendix B10. Model Order to File Special Report Regarding Physician Group and Healthcare Facility Mergers (January 2021)
- Appendix B11. DOJ Antitrust Division Updated Guidance Regarding the Use of Arbitration and Case Selection Criteria
- Appendix B12. FTC's The Most Frequently Asked HSR Questions
- Appendix B13. FTC Tips on Withdrawing and Refiling an HSR Premerger Notification Filing
- Appendix B14. Washington AG Guidance on Healthcare Transactions Notification Requirement
- Appendix B15. US GAO Report - Federal Antitrust Policy: Stakeholders' Perspectives Differed on the Adequacy of Guidance for Collaboration among Health Care Providers
- Appendix B16. FTC Announcement: The Treatment of Debt as Consideration (regarding HSR Act's notification requirements) (August 26, 2021)
- Appendix B17. FTC Announcement: Statement of the Commission on the Use of Prior Approval Provisions in Merger Orders (October 25, 2021)
- Appendix B18. Sample FTC Proposed Order in *In re Davita, et al* case illustrating re-instituted use of Prior Approval Provisions in merger orders
- Appendix B19. Federal Trade Commission and Justice Department Seek to Strengthen Enforcement Against Illegal Mergers (Press release - January 18, 2022)
- Appendix B20. 2023 DOJ and FTC Merger Guidelines (December 18, 2023)
- Appendix B21. FTC Press Release: FTC, DOJ and HHS Work to Lower Health Care and Drug Costs, Promote Competition to

HEALTH CARE & ANTITRUST LAW

- Benefit Patients, Health Care  
Workers (December 7, 2023)
- Appendix B22. Federal Trade Commission Statement  
Concerning Brand Drug  
Manufacturers' Improper Listing of  
Patents in the Orange Book  
(September 14, 2023)
- Appendix B23. Deputy Attorney General Lisa O.  
Monaco Announces New Safe Harbor  
Policy for Voluntary Self-Disclosures  
Made in Connection with Mergers  
and Acquisitions (October 4, 2023)
- Appendix B24. Statement of Chair Lina M. Khan  
Joined by Commissioner Rebecca  
Kelly Slaughter In the Matter of  
Sanofi/Maze Therapeutics (December  
20, 2023)
- Appendix B25. FTC Statement on Second Circuit  
Order Upholding "Pharma Bro"  
Martin Shkreli's Lifetime Ban  
(January 23, 2024)
- Appendix B26. Revised Jurisdictional Thresholds for  
Section 7A of the Clayton Act for  
Hart-Scott-Rodino Premerger  
Notification Filings (January 2024)
- Appendix C. Business Review Letters: Department  
of Justice
- Appendix C1. Business Review Letter to Gales Rexall  
Drug (Nov. 17, 1975)
- Appendix C2. Business Review Letter to California  
Pharmaceutical Association (Sept. 30,  
1976)
- Appendix C3. Business Review Letter to  
International Chiropractors  
Association (March 2, 1977)
- Appendix C4. Business Review Letter Relating to  
Wisconsin Rate Review Program  
(July 5, 1977)
- Appendix C5. Business Review Letter to American  
Hospital Association (June 12, 1978)
- Appendix C6. Business Review Letter to Morros &  
Associates (Aug. 14, 1978)

- Appendix C7. Business Review Letter to American Medical Association (March 9, 1979)
- Appendix C8. Business Review Letter to American Association of Ophthalmology (July 3, 1979)
- Appendix C9. Business Review Letter to Central Virginia Health Systems Agency (May 8, 1980)
- Appendix C10. Business Review Letter to Westlake Health Campus Association (Aug. 27, 1980)
- Appendix C11. Business Review Letter to Maryland Health Care Coalition (Feb. 19, 1982)
- Appendix C12. Business Review Letter to Southwestern Michigan Health Systems Agency (March 2, 1982)
- Appendix C13. Business Review Letter to Ohio Hospital Purchasing Consortium (June 9, 1982)
- Appendix C14. Business Review Letter to Health Care Management Associates (Sept. 21, 1983)
- Appendix C15. Business Review Letter to Hospital Corporation of America (Sept. 21, 1983)
- Appendix C16. Business Review Letter to Stark County Health Care Coalition (Aug. 30, 1985)
- Appendix C17. Business Review Letter to Lexecon Health Service (June 20, 1986)
- Appendix C18. Business Review Letter to Pharmaceutical Care Network (Oct. 3, 1986)
- Appendix C19. Business Review Letter to Service For You (Oct. 3, 1986)
- Appendix C20. Antitrust Division Letter to American Medical Association (Dec. 2, 1986)
- Appendix C21. Business Review Letter to American Red Cross (Dec. 12, 1986)
- Appendix C22. Business Review Letter to North

HEALTH CARE & ANTITRUST LAW

- Mississippi Health Services (April 9, 1987)
- Appendix C23. Business Review Letter to Independent Drug Wholesalers Group (May 18, 1987)
- Appendix C24. Business Review Letter to Danbury Surgical Associates (Aug. 28, 1987)
- Appendix C25. Business Review Letter to St. Louis Area Business Health Coalition (March 24, 1988)
- Appendix C26. Business Review Letter to Baxter Healthcare Corporation (July 29, 1988)
- Appendix C27. Business Review Letter to American Heart Association (April 28, 1989)
- Appendix C28. Business Review Letter to Hyatt Imler Ott & Blount, P.C. (June 12, 1992)
- Appendix C29. Business Review Letter to Transplant Associates (Oct. 26, 1992)
- Appendix C30. Business Review Letter to Case Western Reserve University School of Medicine (Jan. 7, 1993)
- Appendix C31. Department of Justice Advisory Letter to the Pennsylvania Insurance Commissioner (Sept. 7, 1993)
- Appendix C32. Business Review Letter to National Cardiovascular Network, Inc. (Sept. 28, 1993)
- Appendix C33. Business Review Letter to Pharmaceutical Manufacturers Association (Oct. 1, 1993)
- Appendix C34. Business Review Letter to the Health and Personal Care Distribution Conference, Inc. (Oct. 13, 1993)
- Appendix C35. Business Review Letter to St. Anthony Medical Center (Nov. 8, 1993)
- Appendix C36. Business Review Letter to California Chiropractic Association (Dec. 8, 1993)
- Appendix C37. Business Review Letter to Bay Area

- Business Group on Health (Feb. 18, 1994)
- Appendix C38. Business Review Letter to New Jersey Hospital Association (Feb. 18, 1994)
- Appendix C39. Business Review Letter to Houston Health Care Coalition (Mar. 23, 1994)
- Appendix C40. Department of Justice Advisory Letter to Sen. Howard Metzenbaum (Apr. 14, 1994)
- Appendix C41. Business Review Letter to Hotel Employees and Restaurant Employees International Union Welfare Fund (May 20, 1994)
- Appendix C42. Business Review Letter to Birmingham Cooperative Clinical Benchmarking Demonstration Project (June 20, 1994)
- Appendix C43. Business Review Letter to Seeskin, Paas, Blackburn & Co. (June 29, 1994)
- Appendix C44. Business Review Letter to Des Moines Collaborative Provider Organization, Inc. (July 6, 1994)
- Appendix C45. Business Review Letter to Preferred Podiatric Network Inc. and the New York State Podiatric Medical Association (Sept. 14, 1994)
- Appendix C46. Business Review Letter to International Chiropractor's Association of California (Oct. 27, 1994)
- Appendix C47. Business Review Letter to Physician Care, Inc. (Oct. 28, 1994)
- Appendix C48. Business Review Letter to Pulmonary Associates, Ltd., and Albuquerque Pulmonary Consultants, P.A. (Oct. 31, 1994)
- Appendix C49. Business Review Letter to Chicagoland Radiological Network (Dec. 8, 1994)
- Appendix C50. Business Review Letter to Northwestern National Life Insurance Company (March 9, 1995)

HEALTH CARE & ANTITRUST LAW

- Appendix C51. Business Review Letter to Hillhaven Corp. (March 29, 1995)
- Appendix C52. Business Review Letter to Mid-South Health Plan (March 30, 1995)
- Appendix C53. Business Review Letter to AdvNet, Inc. (May 12, 1995)
- Appendix C54. Business Review Letter to Pennsylvania Orthotics & Prosthetics Enterprise (July 17, 1995)
- Appendix C55. Business Review Letter to Hanger Orthopedic Group, Inc. (Sept. 15, 1995)
- Appendix C56. Business Review Letter to Dr. Oswald L. Mikell Regarding Proposed Network of Dermatologists (Nov. 1, 1995)
- Appendix C57. Business Review Letter to Southwest Oncology Group (Nov. 2, 1995)
- Appendix C58. Business Review Letter to Georgia Preferred Podiatric Medical Network (Nov. 3, 1995)
- Appendix C59. Business Review Letter to Dermnet, Inc. (Dec. 5, 1995)
- Appendix C60. Business Review Letter to Preferred Laboratory Access Network (Dec. 7, 1995)
- Appendix C61. Business Review Letter to Oklahoma Physicians Network-IPA, Inc. and PROklahoma Care, Inc. (Jan. 17, 1996)
- Appendix C62. Business Review Letter to Children's Healthcare, P.A. (March 1, 1996)
- Appendix C63. Business Review Letter to Southern Health Corporation (March 5, 1996)
- Appendix C64. Business Review Letter to Orange Los Angeles Medical Group, Inc. (March 8, 1996)
- Appendix C65. Business Review Letter to Itasca Clinic and Grand Rapids Medical Associates (March 19, 1996)
- Appendix C66. Business Review Letter to Allergy &

- Asthma Consultants, Inc. (March 19, 1996)
- Appendix C67. Business Review Letter to Hospice Network of New Jersey, Inc. (April 24, 1996)
- Appendix C68. Business Review Letter to Plastic Surgery Associates of Connecticut, LLC (June 28, 1996)
- Appendix C69. Business Review Letter to Allied Colon and Rectal Specialists (July 1, 1996)
- Appendix C70. Business Review Letter Primary and Specialist Medical Center, L.L.C. (July 2, 1996)
- Appendix C71. Business Review Letter to El Paso Surgical Group (July 24, 1996)
- Appendix C72. Business Review Letter to Sierra CommCare, Inc. (Aug. 15, 1996)
- Appendix C73. Business Review Letter to Home Care Alliance, Inc. (Oct. 4, 1996)
- Appendix C74. Business Review Letter to Cincinnati Regional Orthopaedic and Sports Medicine Associates, Inc. (CROSMA) (Oct. 4, 1996)
- Appendix C75. Business Review Letter to Terence L. Smith, M.D. (Oct. 17, 1996)
- Appendix C76. Business Review Letter to RWHC Network, Inc. (Nov. 12, 1996)
- Appendix C77. Business Review Letter to Marin General Hospital and Ross Hospital (Feb. 11, 1997)
- Appendix C78. Business Review Letter to Sante Fe, New Mexico Managed Care Organization (Feb. 12, 1997)
- Appendix C79. Business Review Letter to Orthopaedic Associates of Mobile, P.A., and Bone & Joint Center of Mobile (Apr. 16, 1997)
- Appendix C80. Business Review Letter to CVT Surgical Center and Vascular Surgery Associates of Baton Rouge (Apr. 16, 1997)

HEALTH CARE & ANTITRUST LAW

- Appendix C81. Business Review Letter to Southwest Orthopedic Specialists (June 10, 1997)
- Appendix C82. Business Review Letter to Gastroenterology Associates, Ltd.; GI Associates, P.C.; and Valley Gastroenterologists (July 7, 1997)
- Appendix C83. Business Review Letter to Vermont Physicians Clinic (July 30, 1997)
- Appendix C84. Business Review Letter to First Priority Health (Nov. 3, 1997)
- Appendix C85. Business Review Letter to the American Heart Association Pharmaceutical Roundtable (Mar. 20, 1998)
- Appendix C86. Business Review Letter to the Heritage Alliance and Lackawanna Physicians Organization (Sept. 15, 1998)
- Appendix C87. Business Review Letter to Santa Fe, New Mexico Managed Care Organization (Sept. 16, 1998)
- Appendix C88. Business Review Letter to NSM Purchasing Association (Jan. 13, 1999)
- Appendix C89. Business Review Letter to Preferred Physicians Medical Group (July 23, 1999)
- Appendix C90. Antitrust Division Business Review Letter to Midwest Behavioral Health LLC (Feb. 4, 2000)
- Appendix C91. Business Review Letter to Rio Grande Eye Associates, P.A. (Aug. 29, 2001)
- Appendix C92. Business Review Letter to Olympus America, Inc. (Aug. 29, 2001)
- Appendix C93. Business Review Letter to Michigan Hospital Group, Inc. (April 2, 2002)
- Appendix C94. Business Review Letter to Washington State Medical Association (Sept. 23, 2002)
- Appendix C95. [Superseded]
- Appendix C96. [Superseded]

- Appendix C97. Business Review Letter to Linen Systems for Healthcare, LLC (Aug. 8, 2006)
- Appendix C98. Business Review Letter to Diana West (May 25, 2004)
- Appendix C99. Letter from Mark J. Botti, Chief, Litigation I Section, Antitrust Division, to the South Carolina State Health Planning Committee Concerning Certificate-of-Need Regulation (Dec. 8, 2006)
- Appendix C100. Letter from Joseph Miller, Assistant Chief, Litigation I Section, Antitrust Division, to Sen. Michael D. Bishop, Michigan Senate Majority Leader, Concerning Proposed Standards of the Michigan Certificate of Need Commission
- Appendix C101. Business Review Letter to the CEO Roundtable on Cancer (Sept. 28, 2008)
- Appendix C102. Business Review Letter to Memorial Health, Inc., and St. Joseph's/Candler Health System (Sept. 4, 2009)
- Appendix C103. Business Review Letter to Pacific Business Group on Health Concerning Reimbursement and Quality Information Dissemination Program (Apr. 26, 2010)
- Appendix C104. Business Review Letter to the Greater New York Hospital Association Concerning Hospital Gainsharing Program
- Appendix C105. Antitrust Division Advocacy Letter to Sen. Peter MacGregor, Michigan State Senate Concerning Legislation Addressing Telehealth Services (Nov. 29, 2016)
- Appendix C106. Business review letter to McKesson Corporation ("McKesson"), Cardinal Health, Inc. ("Cardinal"), Owens & Minor, Inc. ("OMI"), Medline Industries, Inc. ("Medline"), and

HEALTH CARE & ANTITRUST LAW

- Henry Schein, Inc. (“Henry Schein”) relating to collaboration among distributors of personal-protective equipment (“PPE”), oxygen, and medications (April 4, 2020)
- Appendix C107. Baxalta, Emergent BioSolutions, Grifols Therapeutics, and CSL Plasma Expedited Business Review Letter (January 12, 2021)
- Appendix C108. Eli Lilly and Company, AbCellera Biologics, Amgen, AstraZeneca, Genentech, and GSK Expedited Business Review Request Pursuant to COVID-19 Expedited Procedure (July 23, 2020)
- Appendix C109. DOJ Antitrust Division Summary of Business Reviews (Since 1993 Issuance of DOJ/FTC Health Care Antitrust Statement of Enforcement Policy)
- Appendix D. Advisory Opinions: Federal Trade Commission Staff
- Appendix D1. FTC Statement Regarding Physician Agreements to Control Medical Prepayment Plans (Oct. 5, 1981)
- Appendix D2. FTC Staff Advisory Opinion to Louisiana Health Care Association (April 23, 1982)
- Appendix D3. FTC Staff Advisory Opinion to Health Care Management Associates (June 7, 1983) (101 F.T.C. 1014)
- Appendix D4. FTC Staff Advisory Opinion to American Podiatry Association (Aug. 18, 1983)
- Appendix D5. FTC Staff Advisory Opinion to North Carolina Chiropractic Association (Feb. 29, 1984)
- Appendix D6. FTC Staff Advisory Opinion to Medical Society of the County of Erie (March 12, 1984)
- Appendix D7. FTC Staff Advisory Opinion to American Podiatry Association (March 13, 1984)

- Appendix D8. FTC Staff Advisory Opinion to Gilbert M. Frimet (March 22, 1984)
- Appendix D9. FTC Staff Advisory Opinion to Kitsap Physicians Service (March 26, 1984)
- Appendix D10. FTC Staff Advisory Opinion to Peer Review Organizations of Ohio Foundation (April 26, 1984)
- Appendix D11. FTC Staff Advisory Opinion to Kitsap Physicians Service (May 22, 1984)
- Appendix D12. FTC Staff Advisory Opinion to Tarrant County Medical Society (May 25, 1984)
- Appendix D13. FTC Staff Advisory Opinion to Tarrant County Medical Society (July 11, 1984)
- Appendix D14. FTC Staff Advisory Opinion to Utah Society of Oral and Maxillofacial Surgeons (Feb. 8, 1985)
- Appendix D15. FTC Staff Advisory Opinion to American Dental Association (Aug. 26, 1985)
- Appendix D16. FTC Staff Advisory Opinion to Private Healthcare Systems (Sept. 24, 1985)
- Appendix D17. FTC Staff Advisory Opinion to American Intra-Ocular Implant Society (Oct. 11, 1985)
- Appendix D18. FTC Staff Advisory Opinion to North Texas Chapter, American College of Surgeons (Dec. 12, 1985)
- Appendix D19. FTC Staff Advisory Opinion to Passaic County Medical Society (Jan. 3, 1986)
- Appendix D20. FTC Staff Advisory Opinion to Michael A. Duncheon (March 17, 1986)
- Appendix D21. FTC Staff Advisory Opinion to the Equitable Life Assurance Society of the United States (March 26, 1986)
- Appendix D22. FTC Staff Advisory Opinion to Association of Quality Health Care (Aug. 28, 1986)
- Appendix D23. FTC Staff Advisory Opinion to Pacific International Health (Aug. 28, 1986)

HEALTH CARE & ANTITRUST LAW

- Appendix D24. FTC Views on HMO Exclusive Contracts (Nov. 5, 1986)
- Appendix D25. FTC Staff Advisory Opinion to Maryland Medical Eye Associates (May 15, 1987)
- Appendix D26. FTC Staff Advisory Opinion to Intracorp (March 25, 1988)
- Appendix D27. FTC Staff Advisory Opinion to Pan American Management Associates (June 27, 1989)
- Appendix D28. FTC Staff Advisory Opinion to American Dental Association (Feb. 15, 1990)
- Appendix D29. FTC Staff Advisory Opinion to Wichita, Kansas, Chamber of Commerce
- Appendix D30. FTC Staff Advisory Opinion to the National Capital Society of Plastic and Reconstructive Surgeons (April 23, 1991)
- Appendix D31. FTC Staff Advisory Opinion to a Physician IPA That Sponsors a PPO (June 20, 1991)
- Appendix D32. FTC Letter to the New Hampshire Senate Regarding “Any-Willing-Provider” Laws (Mar. 17, 1992)
- Appendix D33. FTC Letter to the California Senate Regarding “Any-Willing Provider” Laws (June 26, 1992)
- Appendix D34. FTC Staff Letter to the Montana House of Representatives Involving Denturists (Oct. 30, 1992)
- Appendix D35. FTC Staff Letter to Missouri Board of Chiropractic Examiners Regarding Free or Discounted Services (Dec. 11, 1992)
- Appendix D36. FTC Staff Letter to the Attorney General of Montana Regarding “Any-Willing-Provider” Laws (Feb. 4, 1993)
- Appendix D37. FTC Staff Letter to the Attorney General of North Dakota Regarding Cooperative Arrangements Among

- Hospitals and “Certificate-of-Public-Advantage” Law (Mar. 8, 1993)
- Appendix D38. FTC Letter to Sen. Orrin G. Hatch Regarding Hospital Mergers (June 8, 1993)
- Appendix D39. [Reserved]
- Appendix D40. FTC Staff Advisory Opinion to California Managed Imaging Medical Group, Inc. (Nov. 17, 1993)
- Appendix D41. FTC Advisory Opinion to Presentation Health System (Dec. 21, 1993)
- Appendix D42. FTC Advisory Opinion to American Medical Association and Chicago Medical Society (Feb. 14, 1994)
- Appendix D43. [Reserved]
- Appendix D44. FTC Letter from Michael D. McNeely, Assistant Director, Bureau of Competition, Federal Trade Commission, to Clifton E. Johnson (June 13, 1994)
- Appendix D45. FTC Staff Advisory Opinion to ACMG, Inc. (July 5, 1994)
- Appendix D46. FTC Staff Advisory Opinion to Southeast Managed Care, Inc. (July 5, 1994)
- Appendix D47. FTC Letter to Suffolk County Dental Society (July 6, 1994)
- Appendix D48. FTC Staff Advisory Opinion to Palmetto Dental Alliance (Sept. 23, 1994)
- Appendix D49. FTC Staff Advisory Opinion to Rocky Mountain Cardiovascular Affiliates (Sept. 23, 1994)
- Appendix D50. FTC Staff Advisory Opinion to Oakland Physician Network (March 28, 1995)
- Appendix D51. FTC Staff Advisory Opinion to Erlanger Medical Center and Memorial Hospital (May 31, 1995)
- Appendix D52. FTC Staff Advisory Opinion to California All Health (June 14, 1995)

HEALTH CARE & ANTITRUST LAW

- Appendix D53. FTC Staff Advisory Opinion to Elmore Community Hospital and Community Hospital (June 20, 1995)
- Appendix D54. FTC Staff Advisory Opinion to Northwestern Nevada Orthopaedic Surgery Alliance (July 11, 1995)
- Appendix D55. FTC Staff Advisory Opinion to Otolaryngology Specialty Providers of Georgia (Aug. 15, 1995)
- Appendix D56. FTC Staff Advisory Opinion to Hematology/Oncology Care Specialists of Western Pennsylvania, P.C. (Sept. 21, 1995)
- Appendix D57. FTC Staff Advisory Opinion to Eastern Ohio Physicians Organization, Inc. (Sept. 28, 1995)
- Appendix D58. FTC Staff Advisory Opinion to Central Texas Medical Group (Sept. 28, 1995)
- Appendix D59. FTC Staff Advisory Opinion to Columbine Family Health Center (Nov. 8, 1995)
- Appendix D60. FTC Staff Advisory Opinion to Southern Arizona Therapy Network, Inc. (Dec. 7, 1995)
- Appendix D61. FTC Staff Advisory Opinion to URONET of Louisiana, L.L.C. (Jan. 23, 1996)
- Appendix D62. FTC Staff Advisory Opinion to the American Medical Association (March 26, 1996)
- Appendix D63. Appendix D63-FTC Staff Advisory Opinion to Mayo Medical Laboratories (July 17, 1996)
- Appendix D64. FTC Staff Advisory Opinion to William W. Backus Hospital (June 11, 1996)
- Appendix D65. FTC Letter to Columbus Hospital and Montana Deaconess Medical Center (June 28, 1996)
- Appendix D66. FTC Staff Advisory Opinion to Business Health Companies (Oct. 19, 1996)
- Appendix D67. FTC Staff Advisory Opinion to

- Southwest Florida Oral Surgery  
Associates (Dec. 2, 1996)
- Appendix D68. FTC Staff Advisory Opinion to Ohio  
Ambulance Network, Inc. (Jan. 23,  
1997)
- Appendix D69. FTC Staff Advisory Opinion to Mobile  
Health Resources, L.L.C. (Jan. 23,  
1997)
- Appendix D70. FTC Staff Advisory Opinion to Valley  
Baptist Medical Center (Sept. 19,  
1996)
- Appendix D71. FTC Staff Advisory Opinion to North  
Mississippi Health Services (Oct. 3,  
1996)
- Appendix D72. FTC Staff Advisory Opinion to Business  
Health Companies, Inc. (Oct. 18,  
1996)
- Appendix D73. FTC Staff Advisory Opinion to North  
Ottawa Community Hospital (Oct.  
22, 1996)
- Appendix D74. FTC Staff Advisory Opinion to  
Foundation for the Accreditation of  
Hematopoietic Cell Therapy (Apr. 17,  
1997)
- Appendix D75. FTC Staff Advisory Opinion to  
Yellowstone Physicians, L.L.C. (May  
14, 1997)
- Appendix D76. FTC Staff Advisory Opinion to Henry  
County Memorial Hospital (Apr. 10,  
1997)
- Appendix D77. FTC Staff Advisory Opinion to First  
Look, L.L.C. (June 19, 1997)
- Appendix D78. FTC Staff Advisory Opinion to New  
Jersey Pharmacists Association (Aug.  
12, 1997)
- Appendix D78A. FTC Staff Advisory Opinion to Mesa  
County Physicians Independent  
Practice Association (Nov. 6, 1997)
- Appendix D79. FTC Staff Advisory Opinion to  
Community Hospital, Inc. (Dec. 22,  
1997)

## HEALTH CARE & ANTITRUST LAW

- Appendix D80. FTC Staff Advisory Opinion to the Alliance of Independent Medical Services, LLC (Dec. 22, 1997)
- Appendix D81. FTC Staff Advisory Opinion to North Mississippi Health Services (Jan. 7, 1998)
- Appendix D82. FTC Staff Advisory Opinion to Phoenix Medical Network, Inc. (May 19, 1998)
- Appendix D83. FTC Staff Advisory Opinion to Associates in Neurology (Aug. 13, 1998)
- Appendix D84. FTC Staff Advisory Opinion to Wesley Health Center, Inc. (April 29, 1999)
- Appendix D85. FTC Letter to Texas House of Representatives Concerning Joint Negotiations by Physicians (May 13, 1999)
- Appendix D86. FTC Staff Advisory Opinion to Orange Pharmacy Equitable Network (May 19, 1999)
- Appendix D87. FTC Staff Advisory Opinion to BJC Health System (Nov. 9, 1999)
- Appendix D88. FTC Staff Letter to the District of Columbia Corporation Counsel Concerning Physician Joint-Negotiation Statute (Oct. 29, 1999)
- Appendix D89. FTC Staff Advisory Opinion to Northeast Pharmacy Service Corporation (July 27, 2000)
- Appendix D90. FTC Staff Advisory Opinion to Havard Vanguard Medical Associates, Inc. (Dec. 18, 2001)

## **PART III**

### **APPENDIXES**

- Appendix D91. FTC Staff Advisory Opinion to the Connecticut Hospital Association (Dec. 20, 2001)
- Appendix D92. FTC Staff Letter to Alaska House of Representatives Concerning Physician Joint Negotiation Statute (Jan. 18, 2002)
- Appendix D93. FTC Staff Letter to State of Washington House of Representatives Concerning Physician Joint Negotiation Statute (Feb. 8, 2002)
- Appendix D94. FTC Staff Advisory Opinion to MedSouth, Inc. (Feb. 19, 2002)
- Appendix D95. Letter from Joseph J. Simons, Director, Jeffrey W. Brennan, Assistant Director and R. Ted Cruz, Attorney, Federal Trade Commission, to Honorable Dennis Stapleton, Chairman, Insurance Committee, Ohio House of Representatives, relating to legislative exemption for physician collective bargaining (Oct. 16, 2002)
- Appendix D96. FTC Staff Advisory Opinion to Vquest and Pitt Country Memorial Hospital (Mar. 8, 2002)
- Appendix D97. FTC Staff Letter to Ohio House of Representatives (Oct. 16, 2002)
- Appendix D98. FTC Staff Advisory Opinion to PriMed Physicians (Feb. 6, 2003)
- Appendix D99. FTC Staff Advisory Opinion to Valley Baptist Medical Center (March 13, 2003)
- Appendix D100. FTC Staff Advisory Opinion to

HEALTH CARE & ANTITRUST LAW

- Arkansas Children's Hospital (March 13, 2003)
- Appendix D101. FTC Staff Letter to the Louisiana Attorney General Concerning Tenet Healthcare Corporation's Proposed Acquisition of Sliddell Memorial Hospital (Apr. 1, 2003)
- Appendix D102. FTC Staff Letter to the Tennessee Senate Concerning Bill Regulating Optometry (Apr. 29, 2003)
- Appendix D103. FTC Staff Advisory Opinion to Medical Group Management Association (Nov. 3, 2003)
- Appendix D104. FTC Staff Advisory Opinion to Bay Area Preferred Physicians (Sept. 23, 2003)
- Appendix D105. FTC Staff Advisory Opinion to Dunlap Memorial Hospital (Jan. 6, 1004)
- Appendix D106. FTC Staff Letter to Patrick C. Lynch, Attorney General of Rhode Island (Apr. 8, 2004)
- Appendix D107. [Reserved]
- Appendix D108. FTC Letter to North Dakota Senate re PBM Contractual Relationships (March 8, 2005)
- Appendix D109. Letter to Delegate Purkey Regarding Virginia House Bills 2518 and 160 and Virginia Senate Bill 272 re Optometric Care (March 9, 2005)
- Appendix D110. Staff Advisory Opinion to Stevens Hospital (Apr. 18, 2005)
- Appendix D111. FTC Staff Letter to Rep. Patrick McHenry Concerning Proposed Bill Regulating Pharmacy Benefit Manager Contractual Relationships (July 15, 2005)
- Appendix D112. FTC Staff Advisory Opinion to North Mississippi Health Services (Aug. 16, 2005)
- Appendix D113. FTC Staff Advisory Opinion to Suburban Health Organization, Inc. (Mar. 28, 2006)

- Appendix D114. FTC Staff Advisory Opinion to Alpena Public Schools (June 16, 2006)
- Appendix D115. FTC Staff Advisory Opinion to St. John's Health System (Sept. 13, 2006)
- Appendix D116. Letter from FTC Directors to Terry G. Kilgore, Virginia House of Delegates, Concerning PBM Regulation (Oct. 2, 2006)
- Appendix D117. FTC Bureau of Competition and Bureau of Economics Letter to Nellie Pou, Assemblywoman, New Jersey General Assembly, concerning regulation of pharmacy benefit managers (Apr. 17, 2007)
- Appendix D118. FTC Staff Follow-Up Letter to MedSouth, Inc. (June 18, 2007)
- Appendix D119. FTC Staff Advisory Opinion to Greater Rochester Independent Practice Association (Sept. 17, 2007)
- Appendix D120. FTC Staff Letter to Massachusetts Department of Public Health Concerning Clinic Advertising
- Appendix D121. FTC Staff Letter to Puerto Rico Treasury and Financial Affairs Committee (Jan. 30, 2008) (objecting to bill permitting health-care providers to collectively negotiate fees)
- Appendix D122. FTC Staff Advisory Opinion to Kaiser Foundation Health Plan (Feb. 13, 2008)
- Appendix D123. FTC Staff Letter to Hon. William J. Seitz, Ohio State Senator, Concerning Collective Bargaining by Home Care Providers (Feb. 14, 2008)
- Appendix D124. Letter from Maureen K. Ohlhausen, Director, Office of Policy Planning, Michael R. Baye, Director, Bureau of Economics, Jeffrey Schmidt, Director, Bureau of Competition, and Lydia B. Parnes, Director, Bureau of Consumer Protection, FTC, to Hon. Elaine Nekritz, Illinois State Representative,

HEALTH CARE & ANTITRUST LAW

- Concerning Proposed Regulation of  
Retail Health Care Facilities
- Appendix D125. FTC Staff Letter to Rep. Tom Emmer,  
Minnesota House of Representatives,  
Concerning Rural Health Care  
Cooperative Joint Negotiations (Mar.  
18, 2009)
- Appendix D126. FTC Staff Letter to Hon. James L.  
Seward, Senator, New York Senate,  
Concerning Pharmacy-Benefit-  
Manager Regulation (Mar. 31, 2009)
- Appendix D127. FTC Staff Opinion Letter to TriState  
Health Partners (Apr. 13, 2009)
- Appendix D128. FTC Staff Letter to Hon. Timothy G.  
Burns, Louisiana House of  
Representatives, Concerning In-  
School Dentistry Regulation (May 1,  
2009)
- Appendix D129. [Reserved]
- Appendix D130. FTC Staff Comments to the Louisiana  
State Board of Dentistry Regarding  
Proposed Modifications to Louisiana  
Rules Regarding the Practice of  
Portable and Mobile Dentistry (Dec.  
9, 2009)
- Appendix D131. FTC Staff Advisory Opinion to the  
University of Michigan Concerning  
Non-Profit Institutions Act
- Appendix D132. FTC Staff Advisory opinion to  
Community CarePartners (Non-Profit  
Institutions Act) (July 2, 2010)
- Appendix D133. FTC Staff Comments to the Kentucky  
Cabinet for Health and Family  
Services Concerning Proposed Rule to  
Regulate Limited Service Clinics  
(Jan. 28, 2010)
- Appendix D134. [Reserved]
- Appendix D135. FTC Staff Comments to the Alabama  
State Board of Medical Examiners  
Concerning Proposed Regulation of  
Interventional Pain Management  
Services (Nov. 3, 2010)

- Appendix D136. FTC Staff Comments to the Georgia Board of Dentistry Concerning Proposed Amendments to Rules Governing Supervision of Dental Hygienists (Dec. 30, 2010)
- Appendix D137. FTC Staff Comments to the North Carolina State Board of Opticians Concerning Proposed Regulations for Optical Goods and Optical Goods Businesses (Jan. 13, 2011)
- Appendix D138. Letter from J. Thomas Rosch, Commissioner, FTC, to Donald M. Berwick and Nancy-Ann DeParle Concerning the Antitrust Ramifications of Accountable Care Organizations (Jan. 24, 2011)
- Appendix D139. Letter from Certain U.S. Senators to Christine Varney, Assistant Attorney General, Antitrust Division, and Jon Leibowitz, Chairman, FTC, Concerning Antitrust and Accountable Care Organizations
- Appendix D140. FTC Staff Letter to Hon. Daphne Campbell, Florida House of Representatives Concerning Regulation of Advanced Registered Nurse Practitioners (Mar. 22, 2010)
- Appendix D141. FTC Staff Letter to Hon. Mark Formby, Mississippi House of Representatives, Concerning Regulation of Pharmacy Benefit Managers (Mar. 22, 2011)
- Appendix D142. FTC Staff Letter to Sens. Rodney Ellis and Royce West, Texas State Senate, Concerning Regulation of Advanced Practice Registered Nurses (May 11, 2011)
- Appendix D143. FTC Staff Letter to Rep. Elliott Naishat, Texas House of Representative, Concerning Bill to Permit Health Care Collaboratives (May 18, 2011)
- Appendix D144. Antitrust Division Staff Letter to Rep. Phillip Johnson, Tennessee

HEALTH CARE & ANTITRUST LAW

- Legislature Concerning Repeal of  
State-Action Exemption Legislation  
for Tennessee Public Hospitals (May  
18, 2011)
- Appendix D145. FTC Staff Letter to Members of the  
Connecticut General Assembly  
Concerning a Bill to Establish  
Provider Cooperative Care  
Arrangements (June 8, 2011)
- Appendix D146. FTC Staff Comments to Sen. James L.  
Seward, New York State, Regarding  
Regulation of Mail-Order Pharmacies  
(Aug. 8, 2011)
- Appendix D147. FTC Staff Letter to Hon. Gary Odom,  
Tennessee House of Representatives,  
Concerning a Bill to Regulate Pain  
Management Services (Sept. 28, 2011)
- Appendix D148. FTC Staff Letter to Sen. John Bonacic,  
New York State Senate, Concerning a  
Bill to Permit Collective Negotiations  
Among Providers (Oct. 20, 2011)
- Appendix D149. FTC Staff Letter to Teneale Johnson,  
Maine Board of Dental Examiners,  
Concerning Proposed Rule to Limit  
X-Ray Procedures by Dental  
Hygienists (Nov. 16, 2011)
- Appendix D150. FTC Staff Letter to Hon. Paul  
Hornback, Kentucky State Senate,  
Concerning a Bill Relating to  
Advanced Practice Registered Nurses  
Scope of Practice (Mar. 26, 2012)
- Appendix D151. FTC Staff Letter to Hon. Jeanne  
Kirkton, Missouri House of  
Representatives, Concerning a Bill  
Relating to CRNA Scope of Practice  
(Mar. 27, 2012)
- Appendix D152. FTC Staff Letter to Hon. Thomas P.  
Willmott and Hon. Patrick C.  
Williams, Louisiana State  
Representatives Concerning Advance  
Practice Registered Nurse  
Collaborative Agreements (Apr. 20,  
2012)

- Appendix D153. FTC Staff Letter to Hon. Stephen LaRoque, North Carolina House of Representatives, Concerning Dental Practice Managers (May 25, 2012)
- Appendix D154. FTC Staff Advisory Opinion to Generic Pharmaceutical Association (Aug. 8, 2012)
- Appendix D155. FTC Staff Advisory Opinion to Yakima Valley Memorial Hospital Re: Application of Non-Profit Institutions Act
- Appendix D156. FTC Staff Advisory Opinion to the Methodist Hospital System Concerning Application of Non-Profit Institutions Act (Nov. 30, 2012)
- Appendix D157. FTC Staff Advisory Opinion to Norman Physician Hospital Organization (Feb. 13, 2013)
- Appendix D158. FTC Staff Advocacy Letter to Hon. Theresa W. Conroy, Connecticut State Representative, Concerning Advanced Practice Registered Nurses (Mar. 19, 2013)
- Appendix D159. FTC Staff Letter to Hon. Heather A Steans, Illinois State Senate, Concerning Proposed Legislation Limiting Chronic Pain Treatment by Certified Registered Nurse Anesthetists
- Appendix D160. FTC Staff Letter to Hon. Catherine Osten, Connecticut General Assembly Concerning Proposed Legislation for Physician Collaboration (June 4, 2013)
- Appendix D161. FTC Staff Letter to the Commission on Dental Accreditation Concerning Accreditation of Dental Therapists (Dec. 2, 2013)
- Appendix D162. FTC Staff Letter to Hon. Kay Khan, Massachusetts House of Representatives, Concerning Bill to Remove Supervision Requirements from Nurse Practitioners and Nurse Anesthesiologists (Jan. 17, 2014)

HEALTH CARE & ANTITRUST LAW

- Appendix D163. FTC Staff Advocacy Letter to Sherin Tooks, Commission on Dental Accreditation, Concerning Accreditation Standards for Dental Therapy Education (Dec. 2, 2013)
- Appendix D164. FTC Staff Advocacy Letter to Centers for Medicare and Medicaid Services Concerning Any-Willing-Provider Changes to Medicare Prescription Drug Benefit Programs (Mar. 7, 2014)
- Appendix D165. FTC Staff Advisory Opinion to Quest Analytics Group Concerning the Non-Profit Institutions Act (Mar. 7, 2014)
- Appendix D166. FTC Staff Advocacy Letter to Simone Salloum, Texas State Board of Dental Examiners, Concerning Proposed Rules (Oct. 14, 2014)
- Appendix D167. FTC Staff Advocacy Letter to Sherin Tooks, Commission on Dental Accreditation, Concerning Accreditation Standards for Dental Therapy Education (Dec. 12, 2014)
- Appendix D168. FTC Staff Advocacy Letter to Department of Health & Human Services Concerning Interoperability of Health Information Technology (Apr. 3, 2015)
- Appendix D169. FTC Staff Advocacy Letter to Hon. Jeanne Kirkton, Missouri House of Representatives, Concerning Bill to Remove Advanced Practice Registered Nurse Practice Restrictions (Apr. 21, 2015)
- Appendix D170. FTC Staff Advocacy Letter to the New York State Department of Health Concerning Certificates of Public Advantage (Apr. 22, 2015)
- Appendix D171. FTC Staff Advocacy Letter to Sen. Chip Shields, Oregon State Legislature, Concerning Proposed Bill to Provide Antitrust Immunity for Certain Health Care Information Exchanges and Agreements (May 18, 2015)

- Appendix D172. FTC Staff Advocacy Letter to Hon. Michael Ranzenhofer, New York State Senate, and Hon. Thomas Abinanti, New York State Assembly, Concerning a Bill to Authorize Health Care Hospital Collaboration (June 5, 2015)
- Appendix D173. FTC Staff Advocacy Letter to Hon. Joe Hoppe and Hon. Melissa Hortman, Minnesota House of Representatives, Concerning a Bill to Permit the Disclosure of Competitively Sensitive Health Care Information (June 29, 2015)
- Appendix D174. FTC Staff Advocacy Letter to Hon. Marilyn W. Avila, North Carolina House of Representatives, Concerning a Bill to Modify North Carolina Certificate-of-Need Law (July 10, 2015)
- Appendix D175. FTC Staff Advisory Letter to Susan Puglisi, Virginia Department of Health Concerning Virginia Rules and Regulations Governing Cooperative Agreements (Sept. 17, 2015)
- Appendix D176. FTC Staff Advocacy Letter to Malaka Watson, Tennessee Department of Health, Concerning Tennessee Rules Implementing Laws Relative to Cooperative Agreements and Certificates of Public Advantage (Sept. 24, 2015)
- Appendix D177. Joint Statement of the FTC and Antitrust Division to the Virginia Certificate of Need Work Group (Oct. 26, 2015)
- Appendix D178. FTC Advocacy Letter to Jenny A Horne, South Carolina House of Representatives, Concerning Proposed Legislation Relating to Supervision of Advanced Practice Nurses (Nov. 2, 2015)
- Appendix D179. Joint Statement of the FTC and Antitrust Division on Certificate-of-

HEALTH CARE & ANTITRUST LAW

- Need Laws and Proposed South Carolina Legislation (Jan.16, 2016)
- Appendix D180. FTC Advocacy Letter to Hon. Valencia Seay, Georgia State Senate, Concerning a Bill Relating to the Supervision of Dental Hygienists (Jan. 29, 2016)
- Appendix D181. FTC Staff Advocacy Letter to Hon. Kent Leonhardt, Senate of West Virginia, Concerning a Bill to Place Regulation of Advanced Practice Registered Nurses under the State Board of Medicine and Osteopathy (Feb. 10, 2016)
- Appendix D182. FTC and Department of Justice Advocacy Letter to Hon Bradley H. Jones, Jr., Massachusetts House of Representatives, Concerning a Bill Permitting Optometrists to Treat Glaucoma Patients (Feb. 18, 2016)
- Appendix D183. FTC Staff Advocacy Letter to Hon. Mike Pushkin, West Virginia House of Delegates, Concerning a Bill Providing State-Action Protection to Certain Health-Care Collaborative Activity (Mar. 9, 2016)
- Appendix D184. FTC Advocacy Letter to Rep. Steve Thompson, Alaska State Legislature, Concerning a Bill Permitting Telehealth Services (Mar. 25, 2016)
- Appendix D185. FTC Advocacy Letter to Hon. Tim Burch, Kentucky House of Representatives, Concerning a Bill Regulating Denturists (Mar. 25, 2016)
- Appendix D186. FTC Staff Advocacy Letter to Larry C. Stutts, Alabama State Senate Concerning Antitrust Exemption for Public University Medical School Collaboration Agreements (May 2, 2016)
- Appendix D187. Joint Comments of the FTC and U.S. Department of Justice to the Puerto Rico House of Representatives

- Concerning a Bill Expanding the Practice Scope of Optometrists (May 18, 2016)
- Appendix D188. FTC Advocacy Letter to the Veterans Administration Concerning Proposed Rule on Advanced Practice Registered Nurses Restrictions (July 25, 2016)
- Appendix D189. FTC Staff Advocacy Letter to the Delaware Board of Occupational Therapy Practice Concerning Occupational Therapist Telehealth Supervision (Aug. 3, 2016)
- Appendix D190. FTC Staff Advocacy Letter to the Delaware Board of Dietetics/Nutrition Concerning Provision of Telehealth Dietetic and Nutrition Services (Aug. 16, 2016)
- Appendix D191. FTC Advocacy Letter to the Delaware Board of Speech/Language Pathologists, Audiologists, and Hearing Aid Dispensers Concerning Amendment to Telecommunication and Telehealth Regulations (Nov. 29, 2016)
- Appendix D192. FTC Staff Advocacy Letter to Hon. Peggy Lehner, Ohio State Senate, Concerning a Bill to License Dental Therapists (Mar. 3, 2017)
- Appendix D193. FTC Staff Advocacy Letter to Hon. Suzanne Geist, Nebraska State Senate, Concerning a Bill to Eliminate Certain Occupational Licensing Requirements (Mar. 15, 2017)
- Appendix D194. Joint Statement of the Antitrust Division and the FTC on Certificate-of-Need Laws and Alaska Senate Bill 62 (Apr. 7, 2017)
- Appendix D195. FTC Advocacy Letter to Hon. Frank W. Berry Concerning Certificate of Need Application (Oct. 16, 2017)
- Appendix D196. FTC Advocacy Letter to Hon. Jesse Topper, Pennsylvania House of

HEALTH CARE & ANTITRUST LAW

- Representatives Concerning Certified Nurse Practitioners (Jan. 3, 2018)
- Appendix D197. Statement of the Federal Trade Commission to the Alaska Senate Committee on Labor & Commerce on Certificate-of-Need Laws and Alaska Senate Bill 62 (Feb. 6, 2018)
- Appendix D198. FTC Staff Comment to Washington State Rep. Paul Graves, Regarding S.S.B. 5411/H.B. 1473 (Feb. 9, 2018)
- Appendix D199. FTC Staff Comment on New York's Proposal to Allow Licensure by Endorsement of Canadian Dental Licenses (April 6, 2018)
- Appendix D200. Letter From Markus H. Meier, Assistant Director, Bureau of Competition, Concerning Crouse Health Hospital's Proposal To Sell Discounted Pharmaceutical Products to the Employees, Retirees, and Their Dependents of Its Affiliate, Dated October 20, 2017
- Appendix D201. Guidance From Staff of the Bureau of Competition's Health Care Division on Requesting and Obtaining an Advisory Opinion
- Appendix D202. FTC Press Release: Multilateral Pharmaceutical Merger Task Force Seeks Public Input (May 11, 2021)
- Appendix D203. FTC Order to File a Special Report, (January 13, 2021)
- Appendix D204. FTC Staff Advisory Opinion Letter from Markus Meier to Doylestown Health Foundation—Staff Opinion Letter Concerning Discounted Pharmaceuticals and Medical Devices Under the Non-Profit Institutions Act (September 2, 2021)
- Appendix D205. FTC Staff Policy Paper: FTC Policy Perspectives on Certificates of Public Advantage (August 15, 2022)
- Appendix D206. Federal Trade Commission Staff Submission to New York State Health

- Department Regarding the Certificate of Public Advantage Application of State University of New York Upstate Medical University and Crouse Health System, Inc. (October 7, 2022)
- Appendix D207. FTC Amicus Brief in *Jazz Pharmaceuticals v. Avadel CNS Pharmaceuticals*, 1:21-cv-00691-GBW (D. Del)
- Appendix D208. Summary Report on the FDA/FTC Workshop on a Competitive Marketplace for Biosimilars (Posted February 28, 2023; date on publication: March 9, 2020)
- Appendix D209. Federal Trade Commission and Department of Justice’s 44th Hart-Scott-Rodino Annual Report (FY2021) (February 2023)
- Appendix D210. FTC Staff Comment Regarding North Carolina Senate Bill 743, Purporting to Give State Action Defense to UNC Health’s Collaborative Activities (June 5, 2023)
- Appendix D211. FTC Amicus Brief in *In re Bystolic Antitrust Litigation* (June 20, 2023)
- Appendix D212. Federal Trade Commission Statement Concerning Reliance on Prior PBM-Related Advocacy Statements and Reports That No Longer Reflect Current Market Realities (July 20, 2023)
- Appendix D213. Hart-Scott-Rodino Annual Report - Fiscal Year 2024 (9-17-25)
- Appendix D214. FTC Clarke Edwards Letter to Senator Brad Hutto (SC) Regarding S.45 / H.3580 and S.669 (Regarding practice of Advanced Practice Registered Nurses (“APRNs”)) (9-9-25)

## PART III

### APPENDIXES

- Appendix E.           Speeches
- Appendix E1-E30.   [Reserved]
- Appendix E31.       [Reserved]
- Appendix E32.       [Reserved]
- Appendix E33.       [Reserved]
- Appendix E34.       “Joint Ventures in Evolving Health  
Care Markets,” Mark J. Horoschak,  
Assistant Director, Bureau of  
Competition, Federal Trade  
Commission (Sept. 25, 1993)
- Appendix E35.       [Reserved]
- Appendix E36.       “The Health Care Guidelines and  
Associations—How Associations  
Can Work with the Department of  
Justice,” Anne K. Bingaman,  
Assistant Attorney General,  
Antitrust Division (Feb. 16, 1994)
- Appendix E37.       [Reserved]
- Appendix E38.       [Reserved]
- Appendix E39.       “State Action Immunity for Health  
Care Collaboration after *FTC v.  
Ticor*,” Mark D. Whitener, Acting  
Deputy Director, Bureau of  
Competition, Federal Trade  
Commission (Apr. 6, 1994)
- Appendix E40.       Remarks of Mary Lou Steptoe, Acting  
Director, Bureau of Competition,  
Federal Trade Commission, on  
Premerger Collaboration (Apr. 7,  
1994)
- Appendix E41.       “Combination and Collaboration in  
Health Care Markets: Antitrust as  
a Constraint in a Time of Change,”

HEALTH CARE & ANTITRUST LAW

Mark D. Whitener, Acting Deputy  
Director, Bureau of Competition,  
Federal Trade Commission (Apr. 28,  
1994)

- Appendix E42. [Reserved]
- Appendix E43. [Reserved]
- Appendix E44. [Reserved]
- Appendix E45. “Efficiency Justifications for Hospital  
Mergers,” Mary Lou Steptoe, Acting  
Director, Bureau of Competition,  
Federal Trade Commission (June  
17, 1994)
- Appendix E46. [Reserved]
- Appendix E47. [Reserved]
- Appendix E48. [Reserved]
- Appendix E49. [Reserved]
- Appendix E50. [Reserved]
- Appendix E51. “Recent Developments in the FTC’s  
Antitrust Program for Health Care  
Markets,” Mark J. Horoschak,  
Assistant Director, Bureau of  
Competition, Federal Trade  
Commission (Feb. 16, 1995)
- Appendix E52. [Reserved]
- Appendix E53. [Reserved]
- Appendix E54. “Current Issues in Health Care  
Antitrust: Boycotts, Mergers, and  
Provider Networks,” Mary Lou  
Steptoe, Acting Director, Bureau of  
Competition, Federal Trade  
Commission (April 5, 1995)
- Appendix E55. [Reserved]
- Appendix E56. [Reserved]
- Appendix E57. “Integrated Joint Ventures,” Mary L.  
Azcuena, Commissioner, Federal  
Trade Commission (Aug. 7, 1995)
- Appendix E58. “Vertical Restraints With Horizontal  
Consequences: Competitive Effects  
of ‘Most Favored Customer’  
Clauses,” Jonathan B. Baker,

	Director, Bureau of Economics, Federal Trade Commission (Sept. 28, 1995)
Appendix E59.	[Reserved]
Appendix E60.	[Reserved]
Appendix E61.	[Reserved]
Appendix E62.	[Reserved]
Appendix E63.	Statement of Robert Pitofsky, Chairman, Federal Trade Commission, Before the Committee on the Judiciary, U.S. House of Representatives (Feb. 27, 1996)
Appendix E64.	[Reserved]
Appendix E65.	“Antitrust Analysis of Hospital Networks and Shared Services Arrangements,” Robert L. Leibenluft, Assistant Director, Bureau of Competition, Federal Trade Commission (Oct. 10, 1996)
Appendix E66.	“Comments on the Nuts and Bolts of a Civil Antitrust Investigation by the Department of Justice Involving the Healthcare Industry,” Mark J. Botti, Trial Attorney, Health Care Task Force Antitrust Division (Oct. 25, 1996)
Appendix E67.	“Current Issues in Health Care Antitrust Enforcement at the Federal Trade Commission,” William J. Baer, Director, Bureau of Competition, Federal Trade Commission
Appendix E68.	[Reserved]
Appendix E69.	“A Stepwise Approach to Antitrust Review of Horizontal Agreements,” Joel I. Klein, Assistant Attorney General, Antitrust Division (Nov. 7, 1996)
Appendix E70.	[Reserved]
Appendix E71.	[Reserved]
Appendix E72.	[Reserved]

HEALTH CARE & ANTITRUST LAW

- Appendix E73. “Thoughts on ‘Leveling the Playing Field’ in Health Care Markets,” Robert Pitofsky, Chairman, Federal Trade Commission (Feb. 13, 1997)
- Appendix E74. “Overview of the Advisory Opinion Process at the Federal Trade Commission,” Judith A. Moreland, Attorney, Bureau of Competition, Federal Trade Commission (Feb. 13, 1997)
- Appendix E75. [Reserved]
- Appendix E76. [Reserved]
- Appendix E77. “Statement to the Negotiated Rulemaking Committee on the Shared Risk Exception to the Anti-Kickback Statute,” Robert F. Leibenluft, Assistant Director, Bureau of Competition, Federal Trade Commission (June 18, 1997)
- Appendix E78. [Reserved]
- Appendix E79. “Health Care Mergers: Will We Get Efficiencies Claims Right?,” Debra A. Valentine, General Counsel, Federal Trade Commission (Nov. 14, 1997)
- Appendix E80. “Antitrust Issues Raised by Rural Health Care Networks,” Robert F. Leibenluft, Assistant Director, Health Care, Federal Trade Commission, before the U.S. Department of Health and Human Services (Feb. 20, 1998)
- Appendix E81. [Reserved]
- Appendix E82. Prepared Statement of Robert Pitofsky, Chairman, Federal Trade Commission, before the Committee of the Judiciary, House of Representatives, Concerning H.R. 4277, the “Quality Health-Care Coalition Act of 1998” (Jul. 29, 1998)
- Appendix E83. “Virtual Mergers of Hospitals: When Does the *Per Se* Rule Apply?,” Mark

- J. Botti, Assistant Chief, Litigation  
Section II, Antitrust Division,  
before the American Health  
Lawyers Association Antitrust in  
the Health Care Field Seminar  
(Feb. 14, 2000)
- Appendix E84. [Reserved]
- Appendix E85. “Exclusionary Vertical Agreements,”  
A. Douglas Melamed, Principal  
Deputy Assistant Attorney General,  
Antitrust Division, U.S.  
Department of Justice, before the  
American Bar Association Antitrust  
Section, Washington, D.C. (Apr. 2,  
1998)
- Appendix E86. [Reserved]
- Appendix E87. “Efficiencies in Defense of Mergers:  
Eighteen Months After,” Robert  
Pitofsky, Chairman, Federal Trade  
Commission, before the George  
Mason Law Review Antitrust  
Symposium: The Changing Face of  
Efficiency, Washington, D.C. (Oct.  
16, 1998)
- Appendix E88. “Anticompetitive Aspects of Exclusive  
Dealing and Related Practices,”  
Remarks of Willard K. Tom, Deputy  
Director, Bureau of Competition,  
FTC, before the American Bar  
Association Antitrust Law Section  
Spring Meeting (Apr. 15, 1999)
- Appendix E89. Statement by Joel I. Klein, Assistant  
Attorney General, Antitrust  
Division, U.S. Department of  
Justice, before the House Judiciary  
Committee, on H.R. 1304, The  
Quality Health-Care Coalition Act  
of 1999, Washington, D.C. (June 22,  
1999)
- Appendix E90. Prepared Statement of Robert  
Pitofsky, Chairman, Federal Trade  
Commission, before the House  
Judiciary Committee on H.R. 1304,  
“The Quality Health-Care Coalition  
Act of 1999” (June 22, 1999)

HEALTH CARE & ANTITRUST LAW

- Appendix E91. “Buyer Power Concerns and the *Aetna/Prudential* Merger,” Marius Schwartz, Economics Director of Enforcement, Antitrust Division, before the 5th Annual Health Care Antitrust Forum, Northwestern School of Law (Oct. 20, 1999)
- Appendix E92. “Guideposts in the Analysis: The Federal Trade Commission and U.S. Department of Justice, Antitrust Division Competitor Collaboration Guidelines,” Susan S. DeSanti, Director, Policy Planning, Federal Trade Commission, before the Houston Bar Association (Dec. 7, 1999)
- Appendix E93. [Reserved]
- Appendix E94. [Reserved]
- Appendix E95. [Reserved]
- Appendix E96. Twenty-Five Years of State Antitrust Enforcement Applied to Health Care
- Appendix E97. [Superseded]
- Appendix E98. [Reserved]
- Appendix E99. [Reserved]
- Appendix E100. Sheila F. Anthony, Commissioner, Federal Trade Commission, “Use Your Time Wisely: Do’s and Don’t’s for Effective Advocacy Before the Federal Trade Commission,” text of remarks before the ABA Section of Antitrust Law Annual Meeting, New York, New York (July 11, 2000)
- Appendix E101. [Reserved]
- Appendix E102. “Antitrust Issues in Settlement of Pharmaceutical Patent Disputes,” Prepared Remarks of Thomas B. Leary, Commissioner, Federal Trade Commission, before the Sixth Annual Health Care Antitrust Forum, Northwestern University School of Law, Chicago, Illinois, November 3, 2000

- Appendix E103. “Antitrust Issues in the Settlement of  
Pharmaceutical Patent Disputes,”  
Part II, Thomas B. Leary
- Appendix E104. [Superseded]
- Appendix E105. [Superseded]
- Appendix E106. Antitrust Division Health Care  
Business Review Letters Issued  
(Feb. 5, 2002)
- Appendix E107. [Reserved]
- Appendix E108. [Reserved]
- Appendix E109. [Reserved]
- Appendix E110. Prospective Guidance FTC Advisory  
Opinions (June 26, 2002)
- Appendix E111. [Reserved]
- Appendix E112. Prepared Statement of Timothy J.  
Muris, Chairman, Federal Trade  
Commission, before the Committee  
on Energy and Commerce,  
Subcommittee on Health, United  
States House of Representatives,  
Relating to the Pharmaceutical  
Industry (Oct. 9, 2002)
- Appendix E113. Timothy J. Muris, Chairman, Federal  
Trade Commission, “The Interface  
of Competition and Consumer  
Protection,” Prepared Remarks  
before The Fordham Corporate Law  
Institute’s 29th Annual Conference  
on International Antitrust Law and  
Policy (Oct. 31, 2002)
- Appendix E114. Thomas B. Leary, Commissioner,  
Federal Trade Commission,  
“Efficiencies and Antitrust: A Story  
of Ongoing Evolution,” Prepared  
Remarks before the ABA Section of  
Antitrust Law 2002 Fall Forum  
(Nov. 8, 2002)
- Appendix E115. Timothy J. Muris, Chairman, Federal  
Trade Commission, “Everything Old  
Is New Again: Health Care and  
Competition in the 21st Century,”  
Prepared Remarks before the

HEALTH CARE & ANTITRUST LAW

Northwest University School of  
Law Seventh Annual Competition  
in Health Care Forum (Nov. 7,  
2002)

- Appendix E116. [Reserved]
- Appendix E117. [Reserved]
- Appendix E118. [Superseded]
- Appendix E119. [Superseded]
- Appendix E120. [Superseded]
- Appendix E121. Timothy J. Muris, Chairman, Federal  
Trade Commission, Prepared  
Statement of the Federal Trade  
Commission on the Pharmaceutical  
Industry Before the Committee of  
the Judiciary, United States Senate  
(June 17, 2003)
- Appendix E122. [Superseded]
- Appendix E123. [Superseded]
- Appendix E124. Thomas B. Leary, Commissioner,  
FTC, “Antitrust in Healthcare: A  
Keynote Address,” Prepared  
Remarks Before the ABA Antitrust  
Law Section and the American  
Health Lawyers Association, Forum  
on Antitrust and Healthcare (May  
15, 2003)
- Appendix E125. Susan A. Creighton, Director, Bureau  
of Competition, FTC, “Diagnosing  
Physician-Hospital Organizations,”  
Prepared Remarks Before the  
American Health Lawyers  
Association Program on Legal  
Issues Affecting Academic Medical  
Centers and Other Teaching  
Institutions (Jan. 22, 2004)
- Appendix E126. [Superseded]
- Appendix E127. FTC Statement in Closing  
Investigation of Caremark Rx/  
AdvancePCS Merger (Feb. 11, 2004)
- Appendix E128. Antitrust Division Statement on the  
Closing of its Investigation of

- Anthem, Inc.'s Acquisition of WellPoint Health Networks, Inc. (March 9, 2004)
- Appendix E129. Antitrust Division Background of Closing Investigation of UnitedHealth Group's Acquisition of Oxford Health Plans (July 20, 2004)
- Appendix E130. [Reserved]
- Appendix E131. [Reserved]
- Appendix E132. Pamela Jones Harbour, Commissioner, Federal Trade Commission, "A 'Check-Up' of Selected Health Care Activity at the Federal Trade Commission," Prepared Remarks Before the ABA Antitrust Law Section Spring Meeting (Mar. 30, 2005)
- Appendix E133. [Reserved]
- Appendix E134. Federal Trade Commission, "New Entry Into Hospital Competition," Prepared Testimony Before the Subcommittee on Federal Financial Management, Government Information, and International Security of the Committee on Homeland Security and Governmental Affairs of the U.S. Senate (May 24, 2005)
- Appendix E135. [Superseded]
- Appendix E136. [Superseded]
- Appendix E137. [Superseded]
- Appendix E138. William Blumenthal, General Counsel, Federal Trade Commission, "The Rhetoric of Gun Jumping," Prepared Remarks Before the Association of Corporate Counsel Annual Antitrust Seminar of Greater New York Chapter (Nov. 10, 2005)
- Appendix E139. U.S. Department of Justice Statement on the Closing of the Vermont

HEALTH CARE & ANTITRUST LAW

- Home Health Investigation (Nov. 23, 2005)
- Appendix E140. [Reserved]
- Appendix E141. Jon Leibowitz, Commissioner, FTC, “Exclusion Payments to Settle Pharmaceutical Patent Cases: They’re B-a-c-k!,” Prepared Remarks Before the Second Annual In-House Counsel’s Forum on Pharmaceutical Antitrust (Apr. 24, 2006)
- Appendix E142. Prepared Statement of the FTC Before the Special Committee on Aging, U.S. Senate Concerning Barriers to Generic Entry (July 20, 2006)
- Appendix E142A. David P. Wales, Deputy Director, Bureau of Competition, FTC, “Examining Competition in Group Health Care,” Prepared Statement of the FTC Before the U.S. Senate Committee on the Judiciary (Sept. 6, 2006)
- Appendix E143. [Reserved]
- Appendix E144. J. Thomas Rosch, Commissioner, FTC, “Monopsony and the Meaning of ‘Consumer Welfare’: A Closer Look at *Weyerhaeuser*,” Prepared Remarks Before the 2006 Milton Handler Annual Antitrust Review (Dec. 7, 2006)
- Appendix E145. Mark Botti, Chief, Litigation I Section, Antitrust Division, “Competition in Healthcare and Certificate of Need,” Prepared Testimony Before the General Assembly of the State of Georgia (Feb. 23, 2007)
- Appendix E146. [Reserved]
- Appendix E147. Mark J. Botti, Former Chief, Litigation I Section, Antitrust Division, “Observations on and From the Antitrust Division’s

- Buyer-Side Cases: How Can ‘Lower’  
Prices Violate the Antitrust Laws?”,  
Prepared Remarks Before the ABA  
Section on Antitrust Law Spring  
Meeting (Apr. 19, 2007)
- Appendix E148. [Reserved]
- Appendix E149. [Reserved]
- Appendix E150. [Reserved]
- Appendix E151. Ryan Danks, Trial Attorney, & Joseph  
M. Miller, Acting Chief, Litigation I  
Section, Antitrust Division, “*U.S. v.*  
*AzHAA*: When Does a Group  
Purchasing Organization Become  
an Illegal Monopsonist?,” Prepared  
Remarks Before the AHLA Annual  
Meeting (June 26, 2007)
- Appendix E152. [Superseded]
- Appendix E153. [Superseded]
- Appendix E154. J. Thomas Rosch, Commissioner,  
FTC, “Clinical Integration in  
Antitrust: Prospects for the  
Future,” Prepared Remarks Before  
the AHLA and ABA Antitrust and  
Health Law Section 2007 Antitrust  
in Health Care Seminar (Sept. 17,  
2007)
- Appendix E155. [Reserved]
- Appendix E156. David Wales, Deputy Director,  
Bureau of Competition, FTC,  
Prepared Statement of the FTC  
Before the House Judiciary  
Committee Concerning HR 971,  
“The Community Pharmacy  
Fairness Act of 2007” (Oct. 18,  
2007)
- Appendix E157. “Critical Loss Analysis: A Merger  
Lawyer’s View,” Prepared Slides of  
Jeffrey Schmidt, Director, Bureau  
of Competition, FTC, Before the  
ABA Section of Antitrust 2007 Fall  
Forum (Nov. 16, 2007)
- Appendix E158. [Reserved]

HEALTH CARE & ANTITRUST LAW

- Appendix E159. Prepared Statement of the FTC  
Before the Alaska House of  
Representatives Concerning  
Certificate of Need (Feb. 15, 2008)
- Appendix E160. [Superseded]
- Appendix E161. [Superseded]
- Appendix E162. [Superseded]
- Appendix E163. Prepared Statement of the Federal  
Trade Commission to the Florida  
Senate Concerning Certification of  
Need (Apr. 2, 2008)
- Appendix E164. [Reserved]
- Appendix E165. J. Thomas Rosch, Commissioner,  
FTC, “Litigating Merger  
Challenges: Lessons Learned,”  
Prepared Remarks Before the Bates  
White Fifth Annual Antitrust  
Conference (June 2, 2008)
- Appendix E166. [Reserved]
- Appendix E167. J. Thomas Rosch, Commissioner FTC,  
“Enforcement Strategies in the  
Health Care Industry,” Prepared  
Remarks Before the ABA Health  
Law Section Sixth Annual  
Healthcare Summit (Nov. 17, 2008)
- Appendix E168. J. Thomas Rosch, Commissioner,  
FTC, “How Pay-for-Delay  
Settlements Make Consumers and  
the Federal Government Pay More  
for Much Needed Drugs,” Prepared  
Statement of the FTC Before the  
Subcommittee on Commerce, Trade,  
and Consumer Protection,  
Committee on Energy and  
Commerce, U.S. House of  
Representatives (Mar. 31, 2009)
- Appendix E169. Richard A. Feinstein, Director,  
Bureau of Competition, FTC,  
“Anticompetitive Pay-for-Delay  
Settlements in the Pharmaceutical  
Industry: Why Consumers and the  
Federal Government Are Paying  
Too Much for Prescription Drugs,”

- Prepared Statement of the FTC  
Before the Subcommittee on Courts  
and Competition Policy, Committee  
of the Judiciary, U.S. Senate (June  
3, 2009)
- Appendix E170. Pamela Jones Harbour,  
Commissioner, FTC, “Clinical  
Integration: The Changing Climate  
and What It Means for Care  
Coordination,” Prepared Remarks  
Before the American Hospital  
Association Annual Membership  
Meeting (Apr. 27, 2009)
- Appendix E171. Jon Leibowitz, Chairman, FTC,  
“ ‘Pay-for-Delay’ Settlements in the  
Pharmaceutical Industry: How  
Congress Can Stop Anticompetitive  
Conduct, Protect Consumers’  
Wallets, and Help Pay for Health  
Care Reform (The \$35 Billion  
Solution),” Prepared Remarks  
Before the Center for American  
Progress (June 23, 2009)
- Appendix E172. Richard A. Feinstein, Director,  
Bureau of Competition, FTC, “The  
Importance of Competition and  
Antitrust Enforcement to Lower-  
Cost, Higher-Quality Health Care,”  
Prepared Statement of the FTC  
Before the Senate Subcommittee on  
Consumer Protection, Product  
Safety, and Insurance (Jul. 16,  
2009)
- Appendix E173. [Reserved]
- Appendix E174. J. Thomas Rosch, Commissioner,  
FTC, “Pay-for-Delay Settlements,  
Authorized Generics, and  
Follow-On Biologics: Thoughts on  
How Competition Law Can Best  
Protect Consumer Welfare in the  
Pharmaceutical Context” (Nov. 19,  
2009)
- Appendix E175. Richard A. Feinstein, Director,  
Bureau of Competition, FTC,

HEALTH CARE & ANTITRUST LAW

- “Statement of Bureau of Competition Director on the FTC’s Closure of Its Investigation of Consummated Hospital Merger in Temple, Texas” (Dec. 23, 2009)
- Appendix E176. [Reserved]
- Appendix E177. [Reserved]
- Appendix E178. [Reserved]
- Appendix E179. [Reserved]
- Appendix E180. Department of Justice Press Release Concerning the Proposed Merger of Blue Cross of Michigan and Physicians Health Plan of Mid-Michigan (Mar. 8, 2010)
- Appendix E181. Christine A. Varney, Assistant Attorney General, Antitrust Division, “Antitrust and Healthcare,” Prepared Remarks Before the ABA/AHLA Antitrust in Healthcare Conference (May 24, 2010)
- Appendix E182. Jon Leibowitz, Chairman, FTC, “A Doctor and a Lawyer Walk into a Bar: Moving Beyond Stereotypes,” Prepared Remarks Before the American Medical Association (June 14, 2010)
- Appendix E183. [Reserved]
- Appendix E184. J. Thomas Rosch, Commissioner, FTC, The Antitrust/Intellectual Property Interface: Thoughts on How To Best Wade Through the Thicket in the Pharmaceutical Context (Nov. 17, 2010)
- Appendix E185. Richard A. Feinstein, Director, Bureau of Competition, FTC, Prepared Statement of the Federal Trade Commission Before the Committee on the Judiciary, Subcommittee on Courts and Competition Policy, U.S. House of Representatives, on Antitrust Enforcement in the Health Care Industry (Dec. 1, 2010)

- Appendix E186. Sharis A. Pozen, Chief of Staff, Antitrust Division, Statement Before the Committee on the Judiciary, Subcommittee on Antitrust, Competition Policy, and Consumer Rights, U.S. Senate (Dec. 1, 2010)
- Appendix E187. Edith Ramirez, Commissioner, FTC, “Antitrust, Accountable Care Organizations, and the Promise of Health Care Reform,” Text of Keynote Address Before the 11th Annual Loyola Antitrust Colloquium (Apr. 29, 2011)
- Appendix E188. Statement of J. Thomas Rosch, Commissioner, FTC, Respecting Proposed Regulations Implementing the Affordable Care Act (Mar. 3, 2011)
- Appendix E189. Statement of Bureau of Competition Director Richard Feinstein on the Abandonment by Providence Health & Services of Its Plan to Acquire Spokane Cardiology and Health Clinics Northwest (April 8, 2011)
- Appendix E190. J. Thomas Rosch, Commissioner, FTC, “Patent Settlements, Patent Reform, and Mergers: Recent Developments in Pharmaceutical Antitrust,” Text of Remarks Before the Sixth Annual In-House Counsel Forum on Pharmaceutical Antitrust (May 11, 2011)
- Appendix E191. [Reserved]
- Appendix E192. [Reserved]
- Appendix E193. [Reserved]
- Appendix E194. [Reserved]
- Appendix E195. “Oversight of the Antitrust Enforcement Agencies,” Prepared Statement of the FTC Before the U.S. House of Representatives (Dec. 7, 2011)
- Appendix E196. J. Thomas Rosch, Commissioner,

HEALTH CARE & ANTITRUST LAW

- FTC, “Antitrust Evaluation of Pay-for-Delay Settlements: A Persistent Quest for Balance,” Text of Remarks Before the American Conference Institute’s Paragraph IV Dispute Conference (Dec. 7, 2011)
- Appendix E197. J. Thomas Rosch, Commissioner, FTC, “The One-Size-Fits-All Approach of the Affordable Care Act,” Text of Remarks Before the 2012 InterSession Health Policy Symposium, Cornell University Sloan Program in Health Administration (Jan. 19, 2012)
- Appendix E198. Remarks of Julie Brill, Commissioner, FTC, Before the North Carolina Bar Association’s Antitrust and Trade Regulation Section (Feb. 9, 2012)
- Appendix E199. Sharis A. Pozen, Acting Assistant Attorney General, “Competition and Health Care: A Prescription for High-Quality, Affordable Care,” Text of Remarks Before the World Annual Leadership Summit on Mergers and Acquisitions in Health Care (Mar. 19, 2012)
- Appendix E200. [Reserved]
- Appendix E201. Prepared Statement of the FTC Before the U.S. House of Representatives Concerning H.R. 1946, the “Preserving Our Hometown Independent Pharmacies Act of 2011” (Mar. 29, 2012)
- Appendix E202. J. Thomas Rosch, Commissioner, FTC, “Consummated Merger Challenges—The Past is Never Dead,” Text of Remarks Before the ABA Section of Antitrust Law Spring Meeting (Mar. 29, 2012)
- Appendix E203. Statement of the FTC Concerning the Proposed Acquisition of Medco

- Health Solutions by Express  
Scripts, Inc. (Apr. 2, 2012)
- Appendix E204. [Reserved]
- Appendix E205. Statement of the Department of Justice's Antitrust Division on its Decision to Close its Investigation of Highmark's Affiliation Agreement with West Penn Allegheny Health System (Apr. 10, 2012)
- Appendix E206. Julie Brill, Commissioner, FTC, "Bending the Cost Curve: The View from the Federal Trade Commission," Health Care Ground Rounds (Jul. 30, 2012)
- Appendix E207. Statement of the FTC Before the Joint Committee on Health, West Virginia Legislature, Concerning Advanced Practice Registered Nurses (Sept. 10, 2012)
- Appendix E208. [Reserved]
- Appendix E209. J. Thomas Rosch, Commissioner, FTC, "Pharmaceutical Patent Settlements and the Supreme Court," Prepared Remarks Before CBI's 2nd Annual Life Sciences Compliance, Legal, and Regulatory Congress (Sept. 21, 2012)
- Appendix E210. J. Thomas Rosch, Commissioner, FTC, "Returning the State Action Doctrine to its Moorings," Prepared Remarks for the Lewis Bernstein Memorial Lecture, St. John's University School of Law (Oct. 3, 2012)
- Appendix E211. [Reserved]
- Appendix E212. Antitrust Division Press Release, "Amerigroup Corp's Divestiture of its Virginia Operations Addresses Department of Justice's Concerns with WellPoint Inc.'s Proposed Acquisition of Amerigroup (Nov. 28, 2012)
- Appendix E213. "Looking Back to Move Forward:

HEALTH CARE & ANTITRUST LAW

- Preserving the Progressive Tradition at the FTC Keynote Address” by Commissioner Edith Ramirez, New York State Bar Association Antitrust Law Section Dinner New York, New York (January 24, 2013)
- Appendix E214. Maureen K. Ohlhausen, Commissioner, FTC, “Hospital Consolidation: The Good, The Bad, and The Ugly,” Text of Remarks Before the 2013 National Policy Forum, America’s Health Insurance Plans (Mar. 13, 2013)
- Appendix E215. Federal Trade Commission/ Department of Justice ACO Working Group, “Summary of Activities Following Issuance of the Statement of Antitrust Enforcement Policy Regarding Accountable Care Organizations Participating in the Medicare Shared Savings Program” (Apr. 10, 2013)
- Appendix E216. Federal Trade Commission/ Department of Justice ACO Working Group, “Questions and Answers Relating to Data Used to Calculate Primary Service Area Shares Under the ACO Policy Statement” (Apr. 10, 2013)
- Appendix E217. [Reserved]
- Appendix E218. Julie Brill, Commissioner, FTC, “Promoting Healthy Competition in Health Care Markets: Antitrust, the ACA, and ACOs,” Text of Remarks Before the 2013 National Summit on Provider Market Power (June 13, 2013)
- Appendix E219. Edith Ramirez, Chairwoman, FTC, “Prepared Statement of the FTC Before U.S. Senate Committee on the Judiciary on Pay-for-Delay Deals: Limiting Competition and Costing Consumers” (Jul. 23, 2013)

- Appendix E220. Maureen K. Ohlhausen, Commissioner, FTC, “Section 5: Principles of Navigation,” Before the U.S. Chamber of Commerce, Washington, D.C. (July 25, 2013)
- Appendix E221. Maureen K. Ohlhausen, Commissioner, FTC, “Protecting Consumer Welfare in the U.S. Health Care Sector,” Before the Mentor Group Forum for EU-US Legal-Economic Affairs, Berlin, Germany (Sept. 13, 2013)
- Appendix E222. Joshua D. Wright, Commissioner, FTC, “Recent Antitrust Enforcement Initiatives at the U.S. Federal Trade Commission,” Before the ABA Section of International Law Conference, Beijing, China (Sept. 16, 2013)
- Appendix E223. Joshua D. Wright, Commissioner, FTC, “The FTC’s Role in Shaping Antitrust Doctrine: Recent Successes and Future Targets,” Before the 2013 Georgetown Global Antitrust Symposium Dinner, Washington, D.C. (Sept. 24, 2013)
- Appendix E224. Joshua D. Wright, Commissioner, FTC, “FTC v. Actavis and the Future of Reverse Payment Cases,” Before the Concurrences Journal Annual Dinner, New York, New York (Sept. 26, 2013)
- Appendix E225. Maureen K. Ohlhausen, Commissioner, FTC, “An Ounce of Antitrust Prevention Is Worth a Pound of Consumer Welfare: The Importance of Competition Advocacy and Premerger Notification,” Before the Eleventh Annual Competition Day, Santiago, Chile (Nov. 5, 2013)
- Appendix E226. Edith Ramirez, Chairwomen, Federal Trade Commission, “Oversight of the Enforcement of the Antitrust

HEALTH CARE & ANTITRUST LAW

- Laws,” Before the U.S. House of Representatives, Washington, D.C. (Nov. 15, 2003)
- Appendix E227. Aviv Nevo, Deputy Assistant Attorney General for Economics, Antitrust Division, “Mergers that Increase Bargaining Leverage,” Before the Stanford Institute for Economic Policy Research and Cornerstone Research Conference on Highly Innovative Industries (Jan. 22, 2014)
- Appendix E228. Maureen K. Ohlhausen, Commissioner, FTC, “Health Care Technology: Promoting Competition and Protecting Innovation,” Text of Remarks before the Connecticut Bar Association Antitrust & Trade Regulation and Consumer Law Sections (Feb. 26, 2014)
- Appendix E229. FTC, “Policy Perspectives: Competition and the Regulation of Advanced Practice Nurses” (Executive Summary) (Mar. 2014)
- Appendix E230. Deborah L. Feinstein, Director, Bureau of Competition, FTC, “The Forward-Looking Nature of Merger Analysis,” Text of Remarks (Feb. 6, 2014)
- Appendix E231. Julie Brill, Commissioner, FTC, “Competition in Health Care Markets,” Text of Remarks Before the 2014 Hal White Antitrust Conference (June 9, 2014)
- Appendix E232. Deborah L. Feinstein, Director, Bureau of Competition, FTC, “Antitrust Enforcement in Health Care: Proscription, Not Prescription,” Text of Remarks Before the Fifth National Accountable Care Organization Summit (June 19, 2014)
- Appendix E233. Edith Ramirez, Chairwoman, FTC, “Retrospectives at the FTC:

- Promoting an Antitrust Agenda,”  
Text of Remarks Before the George  
Washington University Law School  
Merger Transactions Symposium  
(June 28, 2013)
- Appendix E234. Martin Gaynor, Director, Bureau of  
Economics, FTC, “Efficiencies  
Analysis: False Dichotomies,  
Modeling, and Applications to  
Health Care,” Text of Remarks  
Before the 2014 American Antitrust  
Institute Annual Conference
- Appendix E235. Joshua D. Wright, Commissioner,  
FTC, “Antitrust Analysis of Reverse  
Payments After Actavis: Three  
Questions and Proposed Answers,”  
Text of Remarks Before the ABA  
Masters Course VII (Oct. 10, 2014)
- Appendix E236. Julie Brill, Commissioner, FTC,  
“What’s Past is Prologue: FTC’s  
Competition and Consumer  
Protection Priorities,” Text of  
Remarks Before the ABA Fall  
Forum (Nov. 6, 2014)
- Appendix E237. William J. Baer, Assistant Attorney  
General, Antitrust Division, “Origin  
of the Species: The 100 Year  
Evolution of the Clayton Act,” Text  
of Remarks Before the ABA Clayton  
Act 100th Anniversary Symposium  
(Dec. 4, 2014)
- Appendix E238. Andrew Gavil, Director, Office of  
Policy Planning, FTC, “Prepared  
Statement of the FTC on  
Competition and the Potential  
Costs and Benefits of Professional  
Licensure,” Before the Committee  
of Small Business, U.S. House of  
Representatives (Jul. 16, 2014)
- Appendix E239. Jonathan Nuechterlein, General  
Counsel, FTC, “How the FTC  
Works: Lessons from the  
Commission’s Supreme Court  
Trifecta,” Text of Remarks Before

HEALTH CARE & ANTITRUST LAW

- the American University  
Administrative Law Review Annual  
Symposium (Mar. 20, 2015)
- Appendix E240. Maureen K. Ohlhausen,  
Commissioner, FTC, “Reflections on  
the Supreme Court’s *North  
Carolina Dental* Decision and the  
FTC’s Campaign to Rein in State  
Action Immunity” (Mar. 31, 2015)
- Appendix E241. Terrell McSweeney, Commissioner,  
FTC, Text of Remarks (Apr. 28,  
2015)
- Appendix E242. Prepared Statement of the FTC  
Before the U.S. House of  
Representatives, “Oversight of the  
Enforcement of the Antitrust Laws”  
(May 15, 2015)

## **PART III**

### **APPENDIXES**

- Appendix E243. Maureen K. Ohlhausen, Commissioner, FTC, “Brother, May I? The Challenge of Competitor Control over Market Entry,” Text of Remarks Before the George Mason School of Law Global Antitrust Economics Conference (May 29, 2015)
- Appendix E244. Julie Brill, Commissioner, FTC, “A Common Goal: The U.S. Federal Trade Commission’s Healthcare Enforcement Program and Its Implications for ACOs,” Text of Remarks Before the Sixth Annual Accountable Care Organization Summit Preconference (June 17, 2015)
- Appendix E245. Maureen K. Ohlhausen, Commissioner, FTC, “When Regulation Protects Privilege Instead of People: Government Restraints of Trade-A Competition Enforcer’s Perspective,” Text of Remarks Before The Antitrust Enforcement Symposium 2015 of the Journal of Antitrust Enforcement (June 27, 2015)
- Appendix E246. Deborah L Feinstein, Director, Bureau of Competition, FTC, “*FTC v. Sysco*: Old School Antitrust With Modern Economic Tools” Text of Remarks Before GCR Live (Sept. 18, 2015)
- Appendix E247. Edith Ramirez, Chairwoman, FTC, “The Horizontal Merger Guidelines Five Years Later,” Text of Remarks Before the Georgetown University Law Center Ninth Annual Global Antitrust Enforcement Symposium (Sept. 29, 2015)

HEALTH CARE & ANTITRUST LAW

- Appendix E248. Bill Baer, Assistant Attorney General, Antitrust Division, Text of Remarks Before the New Health Care Industry Conference: Integration, Consolidation, Competition in the Wake of the Affordable Care Act (Nov. 15, 2015)
- Appendix E249. Prepared Statement of the Federal Trade Commission Before the United States Senate Committee on the Judiciary, “License to Compete: Occupational Licensing and the State Action Doctrine” (Feb. 2, 2016)
- Appendix E250. Terrell McSweeney, Commissioner, FTC, “Reflections on an Active Year in Merger Enforcement” (Feb. 5, 2016)
- Appendix E251. Prepared Statement of the Federal Trade Commission Before the United States Senate Committee on the Judiciary, “Oversight of the Enforcement of the Antitrust Law” (Mar. 9, 2016)
- Appendix E252. Edith Ramirez, Chairwoman, FTC, Keynote Address Before the Antitrust in Health Law Conference (May 12, 2016)
- Appendix E253. [Reserved]
- Appendix E254. [Reserved]
- Appendix E255. [Reserved]
- Appendix E256. Statement of the Federal Trade Commission to the Alaska Senate Committee on Labor & Commerce on Certificate-of-Need Laws and SB 62 (February 6, 2018)
- Appendix E257. Maureen K. Ohlhausen, Acting Chairman, FTC, “Advancing Economic Liberty,” Text of Remarks Before the George Mason Law Review’s 20th Annual Antitrust Symposium (Feb. 23, 2017)
- Appendix E258. Maureen K. Ohlhausen, Acting Chairman, FTC, “Death By a Thousand Haircuts: Economic Liberty

- and Occupational Licensure Reform,”  
Prepared Remarks Before the  
Heritage Foundation (Jul. 26, 2017)
- Appendix E259. [Reserved]
- Appendix E260. Maureen K. Ohlhausen, Acting  
Chairman, FTC, “Diagnosing the  
Treatments: Issues in Post-Patent  
Pharmaceutical Markets,” Text of  
Opening Remarks from the FTC  
Workshop in Understanding  
Competition in Prescription Drug  
Markets (Nov. 8, 2017)
- Appendix E261. Maureen K. Ohlhausen, Acting  
Chairman, FTC, “The First Wealth is  
Healing: Protecting Competition in  
Healthcare Markets,” Text of  
Remarks Before the 2017 American  
Bar Association Antitrust Section Fall  
Forum (Nov. 16, 2017)
- Appendix E262. Remarks at Credit Suisse 2018  
Washington Perspectives Conference  
Washington DC (Jan. 10, 2018)
- Appendix E263. Bernard A. Nigro, Jr., Deputy Assistant  
Attorney General, Antitrust Division,  
Text of Remarks as Prepared for the  
Antitrust in Healthcare Conference: A  
Prescription for Competition (May 17,  
2018)
- Appendix E264. [Reserved]
- Appendix E265. [Reserved]
- Appendix E266. [Reserved]
- Appendix E267. Rebecca Kelly Slaughter, Commissioner,  
FTC, “Antitrust and Health Care  
Providers: Policies to Promote  
Competition and Protect Patients,”  
Text of Remarks Before the Center for  
American Progress (May 14, 2019)
- Appendix E268. Joseph J. Simons, Chairman, FTC, “A  
Health Care Check on COPAs:  
Assessing the Impact of Certificates of  
Public Advantage in Health Care  
Markets,” Text of Remarks Before the  
FTC Workshop on Certificates of  
Public Advantage (June 18, 2019)

HEALTH CARE & ANTITRUST LAW

- Appendix E269. Christine S. Wilson, Commissioner, FTC, “Bigger than ‘Big Tech’? The Need to Reform Our Health Care System Using Choice and Competition,” Text of Remarks Before the 2019 Global Antitrust Enforcement Symposium (September 9, 2019)
- Appendix E270. Keynote Remarks of Commissioner Christine S. Wilson at the Council for Affordable Health Coverage (January 16, 2020)
- Appendix E271. Opening Remarks of Chairman Joseph Simons at FDA / FTC Biosimilars Workshop (March 9, 2020)
- Appendix E272. Wilson says pandemic underscores need to establish privacy rules for ‘Big Tech’ (May 18, 2020)
- Appendix E273. Occupational Licensing in Health Care: Sorting the Wheat from the Chaff (June 19, 2020)
- Appendix E274. Statement of Commissioner Rebecca Kelly Slaughter Concerning the Contact Lens Rule (June 22, 2020)
- Appendix E275. Statement of Commissioner Rohit Chopra regarding the Review of the FTC’s Pharmaceutical Merger Enforcement Program (May 11, 2021)
- Appendix E276. Statement of Commissioners Noah Joshua Phillips and Christine S. Wilson regarding the Multilateral Pharmaceutical Merger Task Force (May 11, 2021)
- Appendix E277. “Antitrust Applied: Hospital Consolidation Concerns and Solutions,” Statement before the Committee on the Judiciary Subcommittee on Competition Policy, Antitrust, and Consumer Rights, U.S. Senate, by Martin Gaynor, E.J. Barone University Professor of Economics and Public Policy, Heinz College, Carnegie Mellon University (May 19, 2021)

- Appendix E278. Statement of FTC Office of Public Affairs Director Lindsay Kryzak on District Court’s Decision to Grant Preliminary Injunction Halting New Jersey Hospital Merger (August 4, 2021)
- Appendix E279. Concurring Statement of Commissioner Slaughter and Chair Khan regarding *FTC and State of Rhode Island v. Lifespan Corporation and Care New England Health System* (February 17, 2022)
- Appendix E280. Remarks of Chair Lina M. Khan Regarding the 6(b) Study on Pharmacy Benefit Managers (February 17, 2022)
- Appendix E281. Concurring Statement of Commissioners Noah Joshua Phillips and Christine S. Wilson Regarding Lifespan Corporation and Care New England Health System (February 17, 2022)
- Appendix E282. FTC Statement Regarding Termination of Attempted Merger of Rhode Island’s Two Largest Healthcare Providers (March 2, 2022)
- Appendix E283. FTC Statement of Federal Trade Commission Bureau of Competition Deputy Director John M. Newman on Federal Appeals Court Ruling Affirming Preliminary Injunction to Halt Merger of New Jersey Hospital Networks (March 22, 2022)
- Appendix E284. “The Importance of Vigorous Antitrust Enforcement in Health Care” keynote speech by Deputy Assistant Attorney General Andrew Forman at the ABA’s Antitrust in Healthcare Conference - Washington, DC - Friday, June 3, 2022
- Appendix E285. Statement Of Commissioner Christine S. Wilson In the Matter of HSR Premerger Notification Commission File No. P110014 (February 07, 2023)

HEALTH CARE & ANTITRUST LAW

- Appendix E286. Keynote Remarks of Commissioner Rebecca Kelly Slaughter at the FTC/DOJ Pharmaceutical Task Force Workshop (June 14, 2022)
- Appendix E287. Prepared Statement of the Federal Trade Commission Before the United States Senate Committee on the Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights “Oversight of the Enforcement of the Antitrust Laws” (September 20, 2022)
- Appendix E288. Statement of Chair Lina M. Khan Joined by Commissioner Rebecca Kelly Slaughter and Commissioner Alvaro M. Bedoya On the Adoption of the Statement of Enforcement Policy Regarding Unfair Methods of Competition Under Section 5 of the FTC Act (November 10, 2022)
- Appendix F. Antitrust/Health Care Guidelines
- Appendix F1. Statements of Antitrust Enforcement Policy in Health Care, Issued by the United States Department of Justice and the Federal Trade Commission [Withdrawn by DOJ February 2023]
- Appendix F2. DOJ Letter to Maryland on Board Certification of Medical Physicians (September 10, 2018)
- Appendix F3. Joint DOJ/FTC Letter to Tennessee on CON Laws (March 7, 2019)
- Appendix F4. Joint DOJ/FTC Letter to Alaska on CON Laws (March 11, 2019)
- Appendix F5. FTC and DOJ Frequently Asked Questions About Voluntary Expedited Review Under the Statement of Antitrust Enforcement Policy Regarding ACOs Participating in the Medicare Shared Savings Program (the “Policy Statement”)
- Appendix F6. Joint FDA-FTC Statement Regarding Collaboration to Advance Competition in the Biologic Marketplace (February 3, 2020)

- Appendix F7. FTC Non-Compete Complaint Against Gateway Services, Inc. and Gateway US Holdings, Inc. (9-4-25)
- Appendix F8. FTC Agreement Containing Consent Order Relating to Gateway Services, Inc. and Gateway US Holdings, Inc. (9-4-25)
- Appendix F9. Statement of Chairman Andrew N. Ferguson Joined by Commissioner Melissa Holyoak In the Matter of Gateway Pet Memorial Services (9-4-25)
- Appendix F10. Dissenting Statement of Commissioner Rebecca Kelly Slaughter Regarding Gateway Pet Memorial Services/West Coast (9-4-25)
- Appendix F11. FTC Healthcare Non-Compete Warning Letter Template (9-10-25)
- Appendix F12. FTC Complaint *In the Matter of Centerbridge Seaport Acquisition Fund, L.P.*
- Appendix F13. Agreement Containing Consent Orders *In the Matter of Centerbridge Seaport Acquisition Fund, L.P.*
- Appendix F14. Agreement Containing Consent Order for Express Scripts Defendants *In the Matter of (Insulin) Caremark Rx, Zinc Health Services, et al.*
- Appendix F15. Letter from Office of Policy Planning Acting Director Clarke Edwards to Senator Juan Barnett Concerning Mississippi H.B. 1057 to Address the Practice of Advanced Practice Registered Nurses (January 25, 2026)
- Appendix G. Collaboration Guidelines
- Appendix G1. Antitrust Guidelines for Collaborations Among Competitors
- Appendix H1. Federal Trade Commission & U.S. Department of Justice, Statement of Antitrust Enforcement Policy Regarding Accountable Care Organizations Participating in the

## HEALTH CARE & ANTITRUST LAW

- Medicare Shared Savings Program, including Frequently Asked Questions about voluntary antitrust review letters and Cover Sheet for requesting voluntary review letters [Withdrawn by DOJ February 2023]
- Appendix I1. Statement of Enforcement Principles Regarding “Unfair Methods of Competition” Under Section 5 of the FTC Act (Aug. 13, 2015)
- Appendix J1. U.S. Department of Justice & Federal Trade Commission, Antitrust Guidance for Human Resource Professionals (Oct. 2016)
- Appendix K1. DOJ and FTC Joint Antitrust Statement Regarding COVID-19 (March 2020)
- Appendix L1. Overview of FTC Actions in Health Care Services and Products (December 2025)
- Appendix L2. Overview of FTC Actions in Pharmaceutical Products and Distribution (December 2025)
- Appendix L3. FTC Topic and Yearly Indices of Health Care Antitrust Advisory Opinions by Commission and by Staff (December 2025)
- Appendix M1. Summary of Antitrust Division Health Care Cases (Since August 25, 1983) (2020)
- Appendix M2. DOJ Antitrust Division Healthcare Matters Resolved Without a Case Filed
- Appendix N1. DOJ Antitrust Healthcare Matters Resolved Without a Case Filed
- Appendix N2. Complaint for Temporary Restraining Order and Preliminary Injunction Pursuant to Section 13(b) of the Federal Trade Commission Act [Redacted Public Version] (May 16, 2023)
- Appendix N3. Testimony of Director William Montejo,

- RN Division of Licensing and Certification, Maine Department of Health and Human Services; In Support of LD 97, An Act to Repeal the Hospital and Health Care Provider Cooperation Act To the Joint Standing Committee on Health Coverage, Insurance, and Financial Services (January 31, 2023)
- Appendix N4. The Future of Pharmaceuticals: Examining the Analysis of Pharmaceutical Mergers; FTC-DOJ Workshop Summary (June 1, 2023)
- Appendix N5. DOJ Antitrust Division Economic Analysis Group Discussion Paper: Online Reviews and Hospital Choices, EAG 22-1 December 2022
- Appendix N6. *FTC v. Louisiana Children's Medical Center* Petition (April 20, 2023)
- Appendix N7. Stipulated Order for Permanent Injunction and Equitable Relief, *Federal Trade Commission, Plaintiff, v. Surescripts, LLC* (July 26, 2023)
- Appendix N8. Agreement Containing Consent Order, In the Matter of Amgen Inc. and Horizon Therapeutics plc, FTC File No. DO9414
- Appendix N9. Federal Complaint for Injunction, *FTC v. U.S. Anesthesia Partners, Inc.* (September 21, 2023)
- Appendix N10. FTC Administrative Complaint in matter of Novant Health, Inc. and Community Health Systems, Inc. (January 25, 2024)
- Appendix N11. FTC Interim Staff Report on Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies (July 2024)
- Appendix N12. Statement of Chair Lina M. Khan Joined by Commissioners Alvaro M. Bedoya & Rebecca Kelly Slaughter Regarding the Pharmacy Benefit

HEALTH CARE & ANTITRUST LAW

- Managers Interim Staff Report (July 9, 2024)
- Appendix N13. Statement of Commissioner Rebecca Kelly Slaughter Regarding FTC Staff Interim Report: Pharmacy Benefit Managers (August 1, 2024)
- Appendix N14. Concurring Statement of Commissioner Andrew N. Ferguson Regarding the Pharmacy Benefit Managers Interim Staff Report (July 9, 2024)
- Appendix N15. Assistant Attorney General Jonathan Kanter Announces Task Force on Health Care Monopolies and Collusion (May 9, 2024)
- Appendix N16. FDA Draft Guidance Biosimilar Drugs Comment Letter (August 20, 2024)
- Appendix N17. Administrative Complaint in Lawsuit *In the Matter of Caremark Rx, LLC; Zinc Health Services LLC; Express Scripts, Inc.; Evernorth Health, Inc.; Medco Health Services, Inc.; Ascent Health Services LLC; OptumRx, Inc.; OptumRx Holdings LLC; and Emisar Pharma Services LLC, Respondents*, FTC Matter/File Number 221 0114, Docket Number 9437
- Appendix N18. Statement of FTC Bureau of Competition Deputy Director Rahul Rao on Lawsuit Against PBMs and the Role of Drug Manufacturers in Distorting Competition in the U.S Drug Distribution System (September 20, 2024)
- Appendix N19. Staff Submission to Indiana Health Department Regarding the Certificate of Public Advantage Application of Union Health and Terre Haute Regional Hospital (September 5, 2024)
- Appendix N20. DOJ Antitrust Division Evaluation of Corporate Compliance Programs in Criminal Antitrust Investigations (November 2024)

- Appendix N21. DOJ Complaint in matter of *U.S., et al. v. Unitedhealth Group Incorporated, et al.*, 1:24-cv-03267-JKB, (D. MD)
- Appendix N22. FTC Report: Specialty Generic Drugs: A Growing Profit Center for Vertically Integrated Pharmacy Benefit Managers (January 14, 2025)
- Appendix N23. Statement of Chair Lina M. Khan Joined by Commissioner Rebecca Kelly Slaughter and Commissioner Alvaro M. Bedoya In the Matter of Welsh, Carson, Anderson & Stowe (January 17, 2025)
- Appendix N24. Administrative Complaint In the Matter of GTCR BC Holdings, LLC and Surmodics, Inc., FTC Matter/File Number 241 0095, Docket Number 9440
- Appendix N25. Federal Trade Commission Supplemental Staff Submission to Indiana Health Department Regarding 2025 Certificate of Public Advantage Application of Union Health and Terre Haute Regional Hospital (March 17, 2025)
- Appendix N26. DOJ and FTC Antitrust Guidelines for Business Activities Affecting Workers (January 2025)
- Appendix N27. “Statement of Interest of the United States of America” in the case of *Duffy v. Yardi Systems, Inc.* (3-1-24)
- Appendix N28. Massachusetts Chapter 343 “An Act Enhancing The Market Review Process” (Key Provisions in effect 4-8-25)
- Appendix N29. Welsh, Carson, Anderson & Stowe, In the Matter of—Final Decision and Order
- Appendix N30. Administrative Complaint In the Matter of Edwards Lifesciences Corp. and JenaValve Technology, Inc., Docket No. 9442
- Appendix N31. Warning Letter to Covis Pharma GMBH

HEALTH CARE & ANTITRUST LAW

- Appendix N32. Letter to Azurity Pharmaceuticals
- Appendix N33. Warning Letter to Teva Branded  
Pharmaceutical Products R&D, Inc.
- Appendix N34. Warning Letter to Teva Pharmaceutical  
Industries Ltd. c/o Teva
- Appendix N35. Warning Letter to Amphastar  
Pharmaceuticals Inc.
- Appendix N36. Warning Letter to Mylan Specialty LP
- Appendix N37. Warning Letter to Norton (Waterford)  
Limited
- Appendix N38. Warning Letter to Novartis  
Pharmaceuticals Corp.
- Appendix N39. Price Fixing, Bid Rigging, And Market  
Allocation Schemes: What They Are  
And What To Look For—An Antitrust  
Primer—By the Department of  
Justice, Antitrust Division